GB1568553A - Monospiroalkyl derivatives of prostaglandins - Google Patents
Monospiroalkyl derivatives of prostaglandins Download PDFInfo
- Publication number
- GB1568553A GB1568553A GB3182/77A GB318277A GB1568553A GB 1568553 A GB1568553 A GB 1568553A GB 3182/77 A GB3182/77 A GB 3182/77A GB 318277 A GB318277 A GB 318277A GB 1568553 A GB1568553 A GB 1568553A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hydroxy
- hept
- compound
- radical
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003180 prostaglandins Chemical class 0.000 title description 62
- 229940094443 oxytocics prostaglandins Drugs 0.000 title description 49
- 150000001875 compounds Chemical class 0.000 claims description 223
- -1 alkyl radical Chemical class 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 44
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 43
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 31
- 239000005977 Ethylene Substances 0.000 claims description 31
- LMKPHJYTFHAGHK-UHFFFAOYSA-N cyclodrine Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 239000011541 reaction mixture Substances 0.000 claims description 22
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical group [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 15
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 15
- 231100000252 nontoxic Toxicity 0.000 claims description 15
- 230000003000 nontoxic effect Effects 0.000 claims description 15
- 125000003003 spiro group Chemical group 0.000 claims description 11
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 10
- 239000012442 inert solvent Substances 0.000 claims description 10
- 229910052744 lithium Inorganic materials 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 150000003254 radicals Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 6
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- OXXHLZIOXPLTOO-UHFFFAOYSA-N copper(1+);pent-1-yne Chemical compound [Cu+].CCCC#C OXXHLZIOXPLTOO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- VYRDCTDLTGYFHS-UHFFFAOYSA-M n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine;iodocopper Chemical compound I[Cu].CN(C)P(N(C)C)N(C)C VYRDCTDLTGYFHS-UHFFFAOYSA-M 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims 2
- PNNJYDODNCALKD-UHFFFAOYSA-M benzenethiolate;copper(1+) Chemical compound [Cu+].[S-]C1=CC=CC=C1 PNNJYDODNCALKD-UHFFFAOYSA-M 0.000 claims 1
- UKSFURGLGLVJNV-UHFFFAOYSA-M copper(1+);tributylphosphane;iodide Chemical compound I[Cu].CCCCP(CCCC)CCCC UKSFURGLGLVJNV-UHFFFAOYSA-M 0.000 claims 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 96
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 73
- 238000002360 preparation method Methods 0.000 description 51
- 239000000243 solution Substances 0.000 description 46
- 238000012360 testing method Methods 0.000 description 42
- 230000000694 effects Effects 0.000 description 37
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 230000004044 response Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000002904 solvent Substances 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 230000003595 spectral effect Effects 0.000 description 21
- JRRDISHSXWGFRF-UHFFFAOYSA-N 1-[2-(2-ethoxyethoxy)ethoxy]-2-methoxyethane Chemical compound CCOCCOCCOCCOC JRRDISHSXWGFRF-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 11
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 11
- 210000002460 smooth muscle Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 239000005909 Kieselgur Substances 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 229960002986 dinoprostone Drugs 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 125000002346 iodo group Chemical group I* 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 6
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 125000004043 oxo group Chemical group O=* 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- VTWGNAZOWBHJJX-UHFFFAOYSA-N 2-methylspiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(C)(C(O)=O)CC11CCC1 VTWGNAZOWBHJJX-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 5
- 229960004484 carbachol Drugs 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 4
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 4
- BBMCTIGTTCKYKF-UHFFFAOYSA-N n-Heptanol Natural products CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- FUQHLUSGMOSPRQ-UHFFFAOYSA-N spiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(C(=O)O)CC11CCC1 FUQHLUSGMOSPRQ-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- COUXUSGXNKOFCW-ZZXKWVIFSA-N (e)-3-chloro-1-(2-methylspiro[3.3]heptan-2-yl)prop-2-en-1-one Chemical compound C1C(C)(C(=O)\C=C\Cl)CC11CCC1 COUXUSGXNKOFCW-ZZXKWVIFSA-N 0.000 description 3
- STHCISQFSXXOJJ-IZZDOVSWSA-N (e)-3-chloro-1-spiro[5.5]undecan-3-ylprop-2-en-1-one Chemical compound C1CC(C(=O)/C=C/Cl)CCC11CCCCC1 STHCISQFSXXOJJ-IZZDOVSWSA-N 0.000 description 3
- XIYFTKXPNAEZJA-UHFFFAOYSA-N 1,5-dihydroxypenta-1,4-dien-3-one Chemical compound OC=CC(=O)C=CO XIYFTKXPNAEZJA-UHFFFAOYSA-N 0.000 description 3
- OEVHNAMXJYRIKN-UHFFFAOYSA-N 1-(2-methylspiro[3.3]heptan-2-yl)ethanone Chemical compound C1C(C(=O)C)(C)CC11CCC1 OEVHNAMXJYRIKN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- GHQFLCWTRWIWQS-UHFFFAOYSA-N [1-(benzylsulfonyloxymethyl)cyclobutyl]methyl phenylmethanesulfonate Chemical compound C1CCC1(COS(=O)(=O)CC=1C=CC=CC=1)COS(=O)(=O)CC1=CC=CC=C1 GHQFLCWTRWIWQS-UHFFFAOYSA-N 0.000 description 3
- UQDAEORWFCPQCU-UHFFFAOYSA-N acetic acid;oxolane;hydrate Chemical compound O.CC(O)=O.C1CCOC1 UQDAEORWFCPQCU-UHFFFAOYSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 3
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 3
- 239000012965 benzophenone Substances 0.000 description 3
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- HBKZMLDWOAAKSA-UHFFFAOYSA-N spiro[5.5]undecane-3-carbonyl chloride Chemical compound C1CC(C(=O)Cl)CCC11CCCCC1 HBKZMLDWOAAKSA-UHFFFAOYSA-N 0.000 description 3
- IMZALJRIJNIAON-UHFFFAOYSA-N spiro[5.5]undecane-3-carboxylic acid Chemical compound C1CC(C(=O)O)CCC11CCCCC1 IMZALJRIJNIAON-UHFFFAOYSA-N 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 2
- SRMCCEAXOINPMD-ZPUQHVIOSA-N (1e,4e)-1,5-dichloropenta-1,4-dien-3-one Chemical compound Cl\C=C\C(=O)\C=C\Cl SRMCCEAXOINPMD-ZPUQHVIOSA-N 0.000 description 2
- OTLJAYVHDDMRSW-GORDUTHDSA-N (e)-3-iodo-1-spiro[3.3]heptan-2-ylprop-2-en-1-one Chemical compound C1C(C(=O)/C=C/I)CC11CCC1 OTLJAYVHDDMRSW-GORDUTHDSA-N 0.000 description 2
- PALMMUFUALUVRD-IZZDOVSWSA-N (e)-3-iodo-1-spiro[5.5]undecan-3-ylprop-2-en-1-one Chemical compound C1CC(C(=O)/C=C/I)CCC11CCCCC1 PALMMUFUALUVRD-IZZDOVSWSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- NLVCMFKNVXOJAH-UHFFFAOYSA-N 3-hydroxy-1-(2-methylspiro[3.3]heptan-2-yl)prop-2-en-1-one Chemical compound C1C(C)(C(=O)C=CO)CC11CCC1 NLVCMFKNVXOJAH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102100036465 Autoimmune regulator Human genes 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000006243 carbonyl protecting group Chemical group 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 2
- RYNGLMJYZDBNLT-UHFFFAOYSA-N diethyl spiro[3.3]heptane-2,2-dicarboxylate Chemical compound C1C(C(=O)OCC)(C(=O)OCC)CC11CCC1 RYNGLMJYZDBNLT-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000004996 female reproductive system Anatomy 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 2
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 2
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- RPWMIEJSNOFWTC-UHFFFAOYSA-N spiro[3.3]heptane-2-carbonyl chloride Chemical compound C1C(C(=O)Cl)CC11CCC1 RPWMIEJSNOFWTC-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- RDDOTINHBRWOCE-GORDUTHDSA-N (e)-3-chloro-1-spiro[3.3]heptan-2-ylprop-2-en-1-one Chemical compound C1C(C(=O)/C=C/Cl)CC11CCC1 RDDOTINHBRWOCE-GORDUTHDSA-N 0.000 description 1
- KZNZRLBPFVANKN-ZZXKWVIFSA-N (e)-3-iodo-1-(2-methylspiro[3.3]heptan-2-yl)prop-2-en-1-one Chemical compound C1C(C)(C(=O)\C=C\I)CC11CCC1 KZNZRLBPFVANKN-ZZXKWVIFSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- QKKFOSWLROTDQG-UHFFFAOYSA-N 1,5-dibromopenta-1,4-dien-3-one Chemical compound BrC=CC(=O)C=CBr QKKFOSWLROTDQG-UHFFFAOYSA-N 0.000 description 1
- CTHZICXYLKQMKI-FOSBLDSVSA-N 11-Deoxy-PGE2 Chemical class CCCCC[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1C\C=C/CCCC(O)=O CTHZICXYLKQMKI-FOSBLDSVSA-N 0.000 description 1
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DZUXGQBLFALXCR-BMPPNWMBSA-N 7-[(1R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)\C=C\C1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-BMPPNWMBSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 101100239622 Arabidopsis thaliana MYB11 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical class O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- LWYXFDXUMVEZKS-ZVFOLQIPSA-N Methysergide maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 LWYXFDXUMVEZKS-ZVFOLQIPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- BATGQKJNJRQWTP-UHFFFAOYSA-N OCC1(CCC1)CO.C(C1=CC=CC=C1)S(=O)(=O)OCC1(CCC1)COS(=O)(=O)CC1=CC=CC=C1 Chemical compound OCC1(CCC1)CO.C(C1=CC=CC=C1)S(=O)(=O)OCC1(CCC1)COS(=O)(=O)CC1=CC=CC=C1 BATGQKJNJRQWTP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- DZUXGQBLFALXCR-JQXWHSLNSA-N PGF1beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-JQXWHSLNSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- JPKKQJKQTPNWTR-KQAYXBCTSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 JPKKQJKQTPNWTR-KQAYXBCTSA-N 0.000 description 1
- AEBIBBWVNCPTNL-UHFFFAOYSA-N [1-(hydroxymethyl)cyclobutyl]methanol Chemical compound OCC1(CO)CCC1 AEBIBBWVNCPTNL-UHFFFAOYSA-N 0.000 description 1
- PWKWDCOTNGQLID-UHFFFAOYSA-N [N].[Ar] Chemical compound [N].[Ar] PWKWDCOTNGQLID-UHFFFAOYSA-N 0.000 description 1
- NZHXEWZGTQSYJM-UHFFFAOYSA-N [bromo(diphenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 NZHXEWZGTQSYJM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960003108 brompheniramine maleate Drugs 0.000 description 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical class CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004460 liquid liquid chromatography Methods 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003529 luteolytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YEUQSYYJXXXZCH-RQOWECAXSA-N methyl (z)-7-(5-oxocyclopenten-1-yl)hept-5-enoate Chemical compound COC(=O)CCC\C=C/CC1=CCCC1=O YEUQSYYJXXXZCH-RQOWECAXSA-N 0.000 description 1
- PHKNLVZEDWQDIB-RQOWECAXSA-N methyl (z)-7-(6-oxocyclohexen-1-yl)hept-5-enoate Chemical compound COC(=O)CCC\C=C/CC1=CCCCC1=O PHKNLVZEDWQDIB-RQOWECAXSA-N 0.000 description 1
- KDHIOWQSFJTRQG-UHFFFAOYSA-N methyl 7-(5-oxocyclopenten-1-yl)heptanoate Chemical compound COC(=O)CCCCCCC1=CCCC1=O KDHIOWQSFJTRQG-UHFFFAOYSA-N 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004377 methysergide maleate Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- RMIGTEGRHJUHHM-UHFFFAOYSA-N propan-1-ol;hydrochloride Chemical compound Cl.CCCO RMIGTEGRHJUHHM-UHFFFAOYSA-N 0.000 description 1
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- UKVVPDHLUHAJNZ-PMACEKPBSA-N prostane Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC UKVVPDHLUHAJNZ-PMACEKPBSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- OSNPFTFAUNVQMS-UHFFFAOYSA-N spiro[3.3]heptane-2,2-dicarboxylic acid Chemical compound C1C(C(=O)O)(C(O)=O)CC11CCC1 OSNPFTFAUNVQMS-UHFFFAOYSA-N 0.000 description 1
- YKURSNYSAQRVGJ-UHFFFAOYSA-N spiro[3.3]heptane-3,3-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC11CCC1 YKURSNYSAQRVGJ-UHFFFAOYSA-N 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003583 thiosemicarbazides Chemical class 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/40—Halogenated unsaturated alcohols
- C07C33/44—Halogenated unsaturated alcohols containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
(54) MONOSPI ROA LKYL DERIVATIVES OF PROSTAGLANDINS
(71) We, MILES LABORATORIES INC., a Corporation organised and existing under the laws of the State of Indiana, United States of America, of 1127
Myrtle Street, Elkhart, Indiana 46514, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- This invention relates to monospiroalkyl analogues or derivatives of prostaglandin A, E and F which are useful modifiers of smooth muscle activity. The compounds have valuable pharmacological properties as platelet antiaggregating agents and gastric antisecretory agents. The compounds are also valuable pharmacological agents for increasing femoral blood flow and decreasing blood pressure and heart rate.
Natural prostaglandins are twenty-carbon atom alicyclic compounds related to prostanoic acid which has the following structure:
By convention, the carbon atoms of I are numbered sequentially from the carboxylic carbon atom. An important stereo-chemical feature of I is the transorientation of the side-chains C1-C7 and C13-C20. All natural prostaglandins have this orientation. In I, as elsewhere in this specification, a dashed line (- - -) indicates projection of a covalent bond below the plane of a reference carbon atom (alphaconfiguration), while a wedged line (rl) represents direction above that plane (beta-configuration). Those conventions apply to all compounds subsequently discussed in this specification.
In one system of nomenclature suggested by N. A. Nelson (J. Med. Chem., 17: 911 (1974), prostaglandins are named as derivatives or modifications of the natural prostaglandins. In a second system, the I.U.P.A.C. (International Union of Pure and Applied Chemistry) system of nomenclature, prostaglandins are named as substituted heptanoic acids. Yet a third system of nomenclature is frequently used by those skilled in the prostaglandin art. In this third system (also described by
Nelson), all prostaglandins are named as derivatives or modifications of prostanoic acid (structure 1) or prostane (the hydrocarbon equivalent of structure 1). This system is used by Chemical Abstracts and may become an I.U.P.A.C. accepted system.
Natural prostaglandins have the structures,
in which: L and M may be ethylene or cis-vinylene radicals and the five-membered ring five-membered ring
may be:
(A-class);
(B-class);
(C-class);
(D-class);
(E-class); and
(F-class) Prostaglandins are classified according to the functional groups present in the five-membered ring and the presence of double bonds in the ring or chains. prostaglandins of the A class (PGA or prostaglandins A) are characterized by an oxo group at C9 and double bond at C10-C11 (#10,11); those of the B-class (PGB) have an oxo group at C9 and a double bond at C8-C12 (#8,12); compounds of the C-class (PGC) contain an oxo group at C9 and a double bond at C11-C12 (#11,12); members of the D-class (PGD) have an oxo group at C11 and an alpha-oriented hydroxy group at C9; prostaglandins of the E-class (PGE) have an oxo group at C9 and an alpha-oriented hydroxyl group at C11; and membres of the F-class (PGF) have an alpha-oriented hydroxyl group at C9 and an alpha-oriented hydroxyl group at C11.
Within each of the A, B, C, D, E, and F classes of prostaglandins are three subclassifications based upon the presence of double bonds in the side-chains at C5-C6, C13-C14, or C17-C18. The presence of a trans-unsaturated bond only at
C13-C14 is indicated by the subscript numeral 1; thus, for example, PGE1 (or prostaglandins E1) denotes a prostaglandins of the E-type (oxo group at C9 and an alpha-hydroxyl at C11) with a trans-double bond at C13-C14. The presence of both a trans-double bond at C13-C14 and a cis-double bond at C5-C6 is denoted by the subscript numeral 2; for example, PGE2. Lastly, a trans-double bond at C13-C14, a cis-double bond at C5-C6 and a cis-double bond at C17-C18 is indicated by the subscript numeral 3; for example, PGE3. The above notations apply to prostaglandins of the A, B, C, D, and F series as well, however, in the latter the alpha-orientation of the hydroxyl group at C9 is indicated by the subscript Greek letter α after the numerical subscript.
The three systems of nomenclature as they apply to natural PGF,, are shown below:
Nelson System:
Prostaglandin F3α or PGF3α (shortened from) I.U.P.A.C. System:
7 - [3R,5S - Dihydroxy - 2R - (3S - hydroxy - 1E,5Z - octadienyl) cyclopent - 1R - yli - 5Z - heptanoic acid.
Third System (Chemical Abstracts).' (5Z,9α11α,13E,15S,17Z - 9,11,15 - trihydroxyprosta - 5,13,17 - trien - 1 oic acid.
It is important to note that in all natural prostaglandins there is an alphaoriented hydroxyl group at C19. In the Cahn-Ingold-Preelog system of defining stereochemistry, that C15 hydroxyl group is in the S-configuration. The Cahn-Ingold
Prelog system is used to define stereochemistry of any asymmetric center outside of the carbocyclic ring in all three systems of nomenclature described above. This is in contrast to some prostaglandin literature in which the amp designations are used even at C19.
Il-Deoxy derivatives of PGE and PGF molecules do not occur as such in nature, but constitute a class of compounds which possess biological activity related to the parent compounds. Formula II represents 11-deoxy PGE and PGF compounds when:
respectively
In this formula, and others of this patent specification a serpentine line (~) denotes a covalent bond which can be either in the alpha configuration (projecting below the plane of a reference carbon atom) or in the beta configuration (projecting above the plane of a reference carbon atom).
PGFss molecules also do not occur as such in nature, but constitute a class of compounds which possess biological activity related to the parent compounds.
Formula II represents PGFss compounds when:
9-Deoxy derivatives of PGF do not occur as such in nature, but consitute a class of compounds which possess biological activity related to the parent compounds. Formula II represents 9 - deoxy - PGF compounds when:
9 - Deoxy - A9'0 derivatives of PGF do not occur as such in nature, but constitute a class of compounds which possess biological activity related to the parent compounds. Formula II represents 9 - deoxy - #9.10 PGF compounds when:
9a - Homo- and 9a - homo - 11 - deoxy - derivative of PGE and PGF molecules do not occur as such in nature, but constitute a class of compounds which possess biological activity related to the present compounds. Formula II represents 9a - homo- and 9a - homo - 11 - deoxy - compounds of PGE and PGF when:
is replaced by
which may be
11a - Homo-derivatives of PGE, PGF and PGA molecules do not occur as such in nature, but constitute classes of compounds which are expected to possess biological activity related to the parent compounds. Formula II represents 11a homo- derivatives of PGE, PGF, and PGA molecules when:
is replaced by
which may be
11 - Epi - PGE and PGF molecules do not occur as such in nature, but constitute classes of compounds which possess biological activity related to the parent compounds. Formula II represents 11 - epi - compounds of PGE and PGF when:
8Iso-, 12iso or 8,12-bis iso (ent) prostaglandins do not occur as such in nature, but consistute classes of compounds which possess biological activity related to the parent compounds. Formula II represents 8iso-, 12iso- or 8,12-bis iso (ent) compounds when:
is replaced by
These iso modifications of Formula II may be divided into all of the sub-classes with varying ring oxygenation as described above.
Recent research indicates that prostaglandins are ubiquitous in animal tissues and that prostaglandins, as well as their synthetic analogues, have important biochemical and physiological effects in mammalian endocrine, reproductive, central and peripheral nervous, sensory, gastro-intestinal, hematic, respiratory, cardiovascular, and renal systems.
In mammalian endocrine systems, experimental evidence indicates prostaglandins are involved in the control of hormone synthesis or release in hormone-secretory glands. In rats, for example, PGEl and PGE2 increase release of growth hormone while PGA, increased synthesis of that hormone. In sheep, PGE1 and PGF1αinhibit ovarian progesterone secretion. In a variety of mammals, PGF1α and PGF2α act as luteolytic factors. In mice, PGE1, PGE2, PGF1α and PGF1ss increase thyroid activity. In hypophysectomized rats, PGE1, PGE2 and PGF1a stimulate stereoidogenesis in the adrenal glands.
In the mammalian male reproductive system, PGE, contracts the smooth muscle of the vas deferens. In the female reproductive system, PGE and POF compounds contract uterine smooth muscle. In general, PGE, PGB and PGA compounds relax in vitro human uterine muscle strips, while those of the POF class contact such isolated preparations. PGE compounds in general promote fertility in the female reproductive system while PGF2 < has contragestational effects. PFG2 < also appears to be involved in the mechanism of menstruation. In general, PGE2 exerts potent oxytocic effects inducing labor, while PGF2, induces spontaneous abortions in early pregnancy.
PGFα and PGE compounds have been isolated from a variety of nervous tissue and they seem to act as neurotransmitters. PGE, retards whereas PGF2,t facilitates transmission in motor pathways in the central nervous system. It has been reported that PGE1 and PGE2 inhibit transmitter release from adrenergic nerve endings in the guinea pig.
Prostaglandins stimulate contraction of gastrointestinal smooth muscle in vivo and in vitro. In dogs, PGA1, PGE1 and PGE2 inhibit gastric secretion. PGA1 exhibits similar activity in man.
In most mammalian respiratory tracts, compounds of the PGE and PGF class relax in vitro preparations of tracheal smooth muscle. In that preparation, PGE1 and PGE2 relax while PGF2 contracts the smooth muscle. PGE and PGF compounds are normally found in the human lung, and it is postulated that some cases of bronchial asthma involve an imbalance in the production or metabolism of those compounds.
Prostaglandins are involved in certain hematic mechanisms in mammals.
PGE1, for example, inhibits thrombogenesis in vitro through its effect on blood platelets.
In a variety of mammalian cardiovascular systems, compounds of the PGE and
PGA class are vasodilators whereas those of the PGF, class are vasoconstrictors, by virtue of their action on vascular smooth muscle.
Prostaglandins are naturally found in the kidney and reverse experimental and clinical renoprival hypertension.
The clinical implications of prostaglandins and their analogues are far-ranging and include, but are not limited to the following: in obstetrics and gynecology, they may be useful in fertility control treatment of menstrual disorders, induction of labor, and correction of hormone disorders; in gastroenterology, they may be useful in the treatment of peptic ulcers and various disorders involving motility, secretion, and absorption in the gastrointestinal tract; in the respiratory area, they may be beneficial in therapy of bronchial asthma and other diseases involving bronchoconstriction; in hematology, they may have utility as anti-clogging agents in diseases such as venous thrombosis, thrombotic coronary occlusion and other diseases involving thrombi; in circulatory diseases they have therapeutic utility in hypertension, peripheral vasopathies and cardiac disorders.
For a more complete review of chemical, physiological and pharmacological aspects of the prostaglandin, consult the following references: The Prostaglandins, Vol. I., P. Ramwell, Ed., New York, Plenum Press, 1973; Ann. N.Y. Acad. Sci., 180: 1--568 (1971): and Higgins and Braunwald, J. Am. Med. Assn. 53: 92-112 (1972).
The present invention provides monospiroalkyl analogues of prostaglandin having the following structural formula III:
in formula III:
D is R-hydroxymethylene or S-hydroxymethylene radical;
J is methylene, R-hydroxymethylene or S-hydroxymethylene;
K is a methylene or ethylene provided that K is ethylene only when J is methylene or J and K together form a vinylidene radical;
L is a carbonyl, R-hydroxymethylene or S-hydroxymethylene radical;
Q is an ethylene or Z-vinylene radical;
T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical, carboxyl, or hydroxymethyl radical and
B is a monospiroalkyl radical of the formula
where m is 0, 1 or 2; n is an integer from 1 to 4; p is an integer from 3 to 11; and the sum of the integers m and n is less than or equal to 4 and where G is hydrogen or alkyl of 1 to 3 carbon atoms and pharmacologically acceptable non-toxic salts when
T is a carbonyl radical.
The numbering system and the stereochemistry nomenclature used for the prostaglandins of this invention are according to the I.U.P.A.C. definitive and tentative rules which designate the carboxylic acid side chain as the parent compound. In Formula III, a serpentive line (-) denotes a covalent bond which can be either in the alpha configuration (projecting below the plane of a reference carbon atom) or in the beta configuration (projecting above the plane of a reference carbon atom). As used herein, cis or trans isomerism around double bonds respectively is designated by affixes Z (zusammen) and E (entgegen).
Chirality around asymmetric carbon atoms is designated by affixes R (rectus) and S (sinister).
Analogues or derivatives of the A-, E-, and F-classes of the natural prostaglandins are represented by Formula III. Thus when, L is carbonyl, and J and
K together form a vinylene radical, III represents analogues of the A-class of prostaglandins:
When L is carbonyl, K is methylene or ethylene and J is methylene or hydroxymethylene provided that K is ethylene only when J is methylene, III represents analogues of the E-class, 1 l-deoxy-E- class or 9a-homo-l l-deoxy-E-class of prostaglandins:
When L is carbonyl, K is methylene and J is R-hydroxymethylene or Shydroxymethylene, III represents analogues of the E-class of prostaglandins:
When L is carbonyl and both J and K are methylene, III represents analogues of the 11 - deoxy - E - class of prostaglandin:
When L is carbonyl, K is ethylene and J is methylene, III represents analogues of 9a - homo - 11 - deoxy - PGE class of prostaglandins.
When L is R - hydroxymethylene or S-hydroxymethylene; K is methylene or ethylene, provided that K is ethylene only when J is methylene; J is R hydroxymethylene, S - hydroxymethylene or methylene, III represents analogue of PGFα, PGFss, 11 - deoxy - Fα, 11 - deoxy - Fss, 9a - homo - 11 - deoxy - Fα and 9a - homo - 11 - deoxy - Fss:
When L is R - hydroxymethylene or S - hydroxymethylene; K is methylene; and J is R - hydroxymethylene or S - hydroxymethylene, III represents analogues of PGFα and PGFss
When L in formula IIIf above is S - hydroxymethylene and J is R hydroxymethylene, analogues of the Fa class of prostaglandins are represented.
When L in formula Ilif above is R - hydroxymethyl and J is R hydroxymethylene, analogues of the Fss class of prostaglandins are represented.
When J in formula IIIf above is methylene, analogues of the 11 - deoxy - Fα and 11 - deoxy - Fss are represented.
When in formula IIIf above, K is ethylene and J is methylene, then analogues of the 9a - homo - 11 - deoxy Fα and 9a - homo - 11 - deoxy Fss classes of prostaglandin are represented.
When Q, in formulae IIIa, IIIb, IIIc, IIId, IIIe, IIIf and IIIg above is ethylene, then analogues of the A1, E1, 11 -deoxy - E1, 9a - homo - 11 - deoxy - E1, F1α, F1ss, 11 - deoxy - F1α, 11 - deoxy - F1ss, 9a - homo - 11 - deoxy - F1α and 9a - homo11 - deoxy - F1ss classes of prostaglandins are respectively represented.
When Q, in formulae IIIa, IIIb, IIIc, IIId, IIIe, IIIf and IIIg above is Z-vinylene, then analogues of the A2, E2, 11 - deoxy - E2, 9a - homo - 11 - deoxy - E2, F2α, F2ss, 11 - deoxy - F2α, 11 - deoxy - F2ss, 9a - homo - 11 - deoxy - F2α and 9a - homo 11 - deoxy - F2ss classes of prostaglandins are respectively represented.
When T in formulae IIIa, IIIb, IIIc, IIId, IIIe, IIIf and IIIg above is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or carboxyl, then the C, esters and acids of the various A-, E- and F-classes of prostaglandins are represented.
When T in formulae IIIa, IIIb, IIIc, IIId, IIIe, IIIf and IIIg above is hydroxymethyl, then the C1 alcohols of the varous A-, E- and F-classes of prostaglandins are represented.
When formula III aboye is
then III represents the natural configuration of prostaglandins about the C9 and C,2 positions, and when formula III is
then III represents the 8,12 - bis iso (ent) class of prostaglandins.
The term (dl) as used herein refers to racemic mixtures and where used as a prefix to a particular isomer structure, it designates a racemic mixture of the indicated isomer and its mirror image.
Useful intermediates in the preparation of compounds of formula III are represented by the formula:
wherein:
X is an iodine or bromine atom
A is an acid-labile hydroxyl - protecting group selected from 1 - ethoxyethyl, trimethylsilyl, tert - butyl- dimethylsilyl, 1 - ethoxy - 1 - methylethyl, tetrahydropyran - 2 - yl, or triphenylmethyl radicals; and
B is as defined above. These intermediates are described and claimed in our
Application No. 33373/78, to which reference should be made for further details.
The compounds of this invention (having Formula III) can be prepared via the
1,4-conjugate addition of organocopper reagents to cyclopentenones as reported
by Sih, et aL, (J. Amer. Chem. Soc., 97: 857,865 (1975) and references cited
therein), according to the reaction sequence depicted in Reaction Scheme A.
Table A
'L\js i (I t) (1) Lithium metallic or lower alkyl lithium) (V) (2) Copper(Z) Complex (vr) Q > z 'if (vrI) (VIZI) (+) Wezk acid at 20 to SS*C.
4r 0 Thu (IIIb) ) () Weak acia () WaBR4a1coLo1 and ht.
\))Mal %Maas o QH (Ir Ia) (iiif 0 O2R < CITIb) (Sc) Ester hydrolysis Accordingly the present invention provides a process for preparing the compounds of this invention which comprises contacting a compound of the formula:
wherein X is an iodine or bromine atom; A is an acid - labile hydroxy - protecting group selected from I - ethoxyethyl, trimethylsilyl, tert - butyl - dimethylsilyl, I ethoxy - 1 - methylethyl, tetrahydropyran - 2 - yl and triphenylmethyl radicals; and B is hereinbefore defined, with metallic lithium or lower alkyl lithium in an inert solvent under an inert atmosphere; contacting the reaction mixture with a [hexamethylphosphorous triamide], copper(I)pentyne, trin - n - butylphosphine copper(I)iodide, hexamethylphosphorous triamide - copper(I)iodide or copper(I)triophenolate; and contacting the resultant reaction mixture with a compound of the formula:
wherein J' is a methylene or =CHOA radical where A is a hydroxyl protecting group as defined above; K' is methylene or ethylene provided that K' is ethylene only when J' is methylene; T' is an alkoxycarbonyl, having from 1 to 3 carbon atoms inclusive in the alkyl radical, or -CH2OA radical; and Q is as hereinafter defined; in an inert solvent for a period of time sufficient for a substantial degree of conjugate 1,4 addition to take place to form an acid-labile hydroxyl protected intermediate compound, hydrolyzing the so-formed intermediate compound to obtain a first compound having the formula:
wherein BDQ and K' are as defined above, T" is (C,~, alkoxy)carbonyl or hydroxyacetyl, and J" is methylene, R-hydroxy methylene or S-hydroxymethylene,
a) if desired hydrolyzing the first compound, when T" is alkoxycarbonyl to obtain a second compound having the formula:
wherein B, D, Q, K' and J" are as defined above,
b) if desired reducing the first compound to obtain a third compound having the formula:
wherein B, D, Q, J", K' and T" are as defined above, and/or
c) if desired dehydrating the first compound, when J" is R-hydroxymethylene or S-hydroxymethylene and K' is methylene, to obtain a fourth compound having the formula:
wherein Q, D, B and T" are as defined above.
It will be appreciated that the z 5-enones where L is carbonyl and J and K together form a vinylene radical can be reduced to the corresponding a,,1-enols where L is hydroxymethylene using well known procedures, analogous to the conversion in step 5(b).
In reaction Scheme A, Compound IV, where X is an iodine or bromine radical and A is an acid - labile hydroxyl - protecting group which is 1 - ethoxyethyl, trimethylsilyl, tert - butyl - dimethylsilyl, 1 - ethoxy - 1 - methylethyl, tetrahydropyran - 2 - yl or triphenylmethyl, is typically contacted and reacted with metallic lithium or lower alkyl lithium (Compound V) (or magnesium) at from -800C to 0CC for 0.25 to 3.0 hours in an inert solvent, such as diethyl ether, tetrahydrofuran, hexane, pentane, toluene or mixtures thereof, under an inert atmosphere, such as argon nitrogen. Copper(l) complex (Compound VI) is added, usually as a solution in an inert solvent, to the reaction mixture and the mixture is then stirred at less than -20"C for 0.25 to 1.0 hour. A solution of Compound Vii, where J' is methylene or =CHOA and T' is (C1~3 alkoxy)carbonyl or -CH2OA and
K' is methylene or ethylene provided that K' is ethylene only when J' is methylene, usually in an inert solvent, is added to the reaction mixture which is then allowed to warm to -20"C to 250C over a 0.5 to 5 hour period to yield the intermediate
Compound VIII after quenching with a proton donor. Treatment of the latter compound under hydrolysis conditions such as with a weakly-acidic water mixture, such as acetic acid-water (65:35 V/V) with 10% tetrahydrofuran, under an inert atmosphere at a temperature of 200C to 450C for 0.5 to 48 hours cleaves the acidlabile hydroxyl-protecting groups (described in J. Amer. Chem. Soc.
94:6194[1972]) to yield Compound Illb where K' is as defined above, J" is methylene or =CHOH and T" is (Ct~3 alkoxy)carbonyl or hydroxymethyl.
Where J" and K' of Compound Illb are respectively R- or S-hydroxymethylene and methylene, dehydration of Compound Illb with a weakly-acidic water mixture, such as acetic acid-water, at 600C to 800C (described in J. Org. Chem., 34:3552 [1969]) yields Compound Illa. Compound Illa is also obtained as a byproduct of the acidic hydrolysis of Compound VIII.
Reduction of Compound Illb with sodium borohydride in an alcoholic or other suitable polar solvent (described in J. Org. Chem., 34:3552 [1969]) yields
Compound IIIf.
When T" of Compound Illb (where J" is methylene) or IIIf is (Ct~3 alkoxy)carbonyl, cleavage of the ester group with a base, such as sodium hydroxide or potassium hydroxide in a mixed organic solvent such as water-tetrahydrofuran, water - p - dioxane or water - alcohol (described in J. Amer. Chem. Soc., 94:7823 [1973]) yields the corresponding acid, i.e. where T is carboxyl. Where J" and T" of
Compound Illb are respectively R- or S-hydroxymethylene and (C,~3 alkoxy)carbonyl, cleavage of the ester group by exposure to Rhizopus oryzae (described in J. Amer. Chem. Soc. 95:1676 [1973] or with a suitable esterase or lipase (described in U.S. Patent No. 3,769,166 and German Offenlegungsschrift No.
2,242,792) yields the corresponding acid, i.e. where T" is carboxyl.
Treatment of Compounds Illa or Illb, where T" is carboxyl or (Ct~3 alkoxy)carbonyl group, with a carbonyl protecting group followed by reduction and treatment with nitrous acid yields the corresponding primary alcohol, i.e. where T is hydroxymethyl (described in U.S. Patent No. 3,636,120). Suitable carbonyl protecting groups include lower alkoxyamines, semicarbazide or thiosemicarbazides. Suitable reducing agents include lithium aluminium hydride, lithium borohydride, and diisobutyl aluminium hydride.
Non-toxic, pharmacologically acceptable salts of Compound III can be prepared by neutralization of III where T is carboxyl, with an equivalent or an excess amount of the corresponding non-toxic salt-forming organic or inorganic base. The salts can be prepared by procedures which are well-known in the art.
Suitable salts include sodium, potassium and ammonium salts. The salts may be isolated by lyophilization of the resulting mixture, or by filtration if sufficiently unsoluble, or by similar well-known techniques.
The compounds of this invention can be isolated from reaction mixtures and purified by well-known organic chemistry procedures. For example, the compounds can be isolated by dilution of the reaction mixture with water; extraction with a water-immiscible solvent, such as benzene, cyclohexane, ether, ethyl acetate, methylene chloride or toluene; chromatography or distillation or a combination of these procedures. Purification of these compounds can be accomplished by methods which are well-known in the art for the purification of prostaglandins, lipids, fatty acids, and fatty esters. For example, such methods as reverse phase partition chromatography; counter-current distribution; absorption chromatography on acid washed magnesium silicate, neutral or acid washed silica gel, alumina or silicic acid; preparative paper chromatography; preparative thin layer chromatography; high pressure liquid-liquid chromatography; gas-liquid chromatography or combinations thereof can be used to purify the compounds produced by the processes of this invention.
The starting reactants used in the above procedures are well-known or easily prepared by known methods. For instance, in the reaction sequence depicted in
Reaction Scheme A, Compund V, i.e. metallic lithium or lower alkyl lithium such as t-butyllithium, sec-butyllithium or n-butyllithium is commercially available or can be prepared by well-known organic chemistry met
TABLE: B }Io (1r) (1) SoC12 or 0xalySch1orile or si r reagent.
0 ClAllb (ivy) (2) A1CI3 or other similar Lexis Acib; Acatylenc;CC14 or C}12e12 or similar irtart solvent.
(IYc) - solubla bromide or a other ACetone. a X (ivy) Q) NaSH+ or LiAlR or other similar ?ifl9 qet/o tv ant.
(rv) OH (5) HrdroX l priotecting swe:rot sich tbat A is t 1i1e.
X S (rt) In IVa#IVb, the monospiroalkyl acid IVa is converted to the acid chloride IVb using an acid chloride forming reagent such as thionyl chloride, oxalyl chloride or phosphorus trichloride as described in Fieser & Fieser, Reagents For Organic
Synthesis, 1:1158, J. Wiley & Sons Inc. (1967). In IVb )IVc, the acid chloride IVb is reacted with acetylene in an inert solvent, such as carbon tetrachloride or methylene chloride in the presence of a Lewis acid such as aluminum chloride or stannic chloride to produce the p-chlorovinyl ketone IVc as described in Chem.
Revs. 161 (1965) and Org Synth., IV:186, J. Wiley & Sons Inc. (1963). In IVc#IVd, the ss-chlorovinyl ketone IVc is converted into the corresponding ss - iodo- or ss bromo - vinyl ketone IVd, where X is an iodine or bromine atom, using a soluble salt, such as sodium iodide, sodium bromide or lithium bromide in a polar inert solvent, such as acetone or acetonitrile, as described in J. Amer. Chem. Soc., 94:7210 (1972). In IVdolVe, Compound IVd is reduced to the corresponding P iodo- or p - bromo - vinyl alcohol using a suitable reducing agent, such as sodium borohydride in an alcohol or lithium aluminum hydride in an ether as described in
J. Amer. Chem. Soc., 94:7210 (1972). In IVeelV, Compound IVe is protected with a suitable acid-labile hydroxyl-protecting group (A) by reaction with for example, dihydropyran as ethyl vinyl ether in the presence of an acid catalyst such as p toluenesulfonic acid, 98% sulfuric acid or phosphorous oxychloride; or a trialkylsilyl chloride, such as trimethylsilyl chloride or t - butyldimethylsilyl chloride, or triphenylmethyl bromide in the presence of a basic catalyst such as triethylamine or imidazole. Any protecting group which is removable under mildly acid conditions and is stable to alkyllithium and alkylcopper(l)reagents can also be suitably used, see J. Org. Chem. 37:1947 (1972).
In Reaction Scheme B, compound iVc can be prepared from compound IVa, where B is
where m, n and p are as defined above by reacting IVa with methyl lithium in an
inert solvent such as diethyl ether to produce the spiroalkyl methyl ketone as
described in Org. Reactions, 18:1 (1970). The spiroalkyl methyl ketone is then
dissolved in diethyl ether and methyl formate and treated with sodium hydride to
form the spiroalkyl hydroxyvinyl ketone as described in J. Amer. Chem. Soc.
76:552 (1954). The hydroxyvinyl ketone is then treated with an acid chloride
forming reagent such as thionyl chloride to form the ss - chloro - vinyl ketone IVc
as described in Chem. Revs., 161 m. (1965).
Examples of the corresponding monospiroalkyl compounds having formula iVa include: spiro[3,3]heptylane - 2 - carboxylic acid: spiro[5.5]undecane - 3
carboxylic acid and 2- methylspiro[3.3]heptane - 2- carboxylic acid. The
compounds of formula IVa are either commercially available or easily prepared by
well-known techniques from commercially available materials. For example, the
compound 1,1 - cyclobutanedicarboxylic acid (Beil. 9:725, available from Aldrich
Chemical Co., Inc.) is reduced with lithium aluminium hydride to produce 1,1
di(hydroxymethyl)cyclobutane by a similar procedure as described in Fieser
Fieser, Reagents for Org. Synth., 1:581, J. Wiley & Sons, (1967). This compound is
then esterified with p-toluenesulfonyl chloride to produce I, I di(toluenesulfonyloxymethyl)cyclobutane. This latter compound is cyclized with
diethyl malonate to produce diethyl spiro[3.3]heptane - 2,2 - dicarboxylate followed by hydrolysis in ethanolic potassium hydroxide to produce
spiro[3.3]heptyl - 2,2 - dicarboxylic acid. This compound is then thermally decarboxylated to produce spiro[3.3]heptane - 2 - carboxylic acid which is used in the reaction sequence depicted in Reaction Scheme B to produce 1 - iodo - 3RS (I-ethoxyethoxy) - 3 - (spiro[3.3]hept. - 2 - yl) - 1E-prbpene. These procedures are described collectively in J. Org. Chem., 29:2914 (1964); J. Org. Chem., 31:4069 (1966); and Justus Liebigs Ann. Chem., 685:74 (1965).
Spiro[5.5]undecane - 3 - carboxylic acid (either commercially available or prepared by well-known methods such as described in U.S. Patent No. 3,350,442) is used in the reaction sequence depicted in Reaction Scheme B to produce 1 iodo - 3RS - (I - ethoxyethoxy) - 3 - (spiro[5.5]undec - 3 - yl) - lE - propene.
The compound 2 - methylspiro[3.3]heptane - 2 - carboxylic acid can be prepared from the spiro[3.3]heptane - 2 - carboxylic acid as described in Tet. Let.
2221 (1974) and J. Org. Chem., 35:262 (1970).
The compounds of the present invention represented by Formula III inhibit aggregation of human platelets in vitro as demonstrated in Example 15 below. It is this feature which distinguishes the compounds of this invention over the natural prostaglandins. Of the natural prostaglandins, only PGE, displays a similar activity,.
Preferred compounds of those represented by formula 111 which inhibit aggregation of platelets are the compounds designated TR-4120 and TR-4845. It should be noted that while the natural PGE1 compounds display a similar activity the compounds of the present invention do not exhibit the undesirable side effects observed in the natural PGE, compounds to the same extent, if at all.
The prostaglandin analogues of this invention also stimulate in vitro and in vivo smooth muscle preparations derived from a variety of tissues and organs of experimental animals. Such smooth muscle assays are widely utilized to determine the activity of natural prostaglandins as well as prostaglandin analogues (Bundy et al., Ann. N.Y. Acad. Sci., 180:76 [1961]; Berstrom et al., Pharmacol Revs., 20:1 [1968]). Details of the activity of certain compounds having Formula 111 are presented in Example 15 below. Accordingly the present invention also provides a pharmaceutical composition which comprises a compound of this invention together with a pharmaceutically accepable carrier or diluent.
Compounds of the formulae, collectively referred to as Illx,
wherein J is R-hydroxymethylene or methylene; T and G are as defined above and pharmacologically acceptable nontoxic salts thereof when T is a carboxyl radical are useful in a therapeutic method of inhibiting gastric secretion in an individual for whom such therapy is indicated by administering to that individual an amount of a compound having structure Illx that is effective in inhibiting or decreasing gastric secretion. The term "individual" as utilized in this specification means a human being or a standard experimental animal that is a model for a human being.
Indications for use of compounds IIIx are any conditions in which inhibition or decrease of gastric secretion is desirable, such as peptic or duodenal ulcers and hyperacidity. The term "effective antisecretory amount" or any equivalent of the term means a dose or a series of doses that will decrease or inhibit gastric secretion.
Although that amount will vary from individual to individual and from indication to indication, it is easily determined by one skilled in the art without undue experimentation. Compounds IIIx may be administered by known conventional modes of therapeutic administration such as intravenous, parenteral, buccal, rectal or oral. The oral mode, however, is preferred. Dose forms for administration of compounds IlIx can be prepared by recognized methods in the pharmaceutical sciences. Use of methyl 7 - I3R - hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 (spiro[3.3]hept - 2 - yl) - lE - propenyl]cyclopent - lR - yllheptanoate; 7 - (3R hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 - (spiro[3.3]hept - 2 - yl) - lE - propenyl]cyclopent - lR - yllheptan - 1 - ol; methyl 7 - (3R - hydroxy - 5 - oxo 2R - [3R - hydroxy - 3 - (2 - methylspiro[3.3]hept - 2- yl)- 1E - propenyl]cyclopent - lR - yl}heptanoate; 7 - {3R - hydroxy - 5 - oxo - 2R - [3R hydroxy - 3 - (2 - methylspiro[3.3]hept - 2 - yl) - lE - propenyl]cyclopent - lR yllheptan - 1 - ol; and dl 7 - {5 - oxo - 2R - [3R - hydroxy - 3 - (spiro[3.3]hept 2 - yl) - 1E - propenyl]cyclopent - IR - yl}heptanoic acid is preferred.
The preferred compunds TR-4120 and TR-4845 mentioned above are represented by the formula Illy
where G is hydrogen or methyl, and are particularly useful in a therapeutic method of inhibiting platelet aggregation in an individual for whom such therapy is indicated by administering to that individual an amount of compound Illy that is effective in inhibiting or decreasing platelet aggregation. Indications for use of compound lIly are any condition in which inhibition or decrease of platelet aggregation is desirable, such as ischemic heart disease, high blood pressure and post surgical conditions. The term "effective antiaggregating amount" or any equivalent of the term means a dose or a series of doses that will decrease or inhibit platelet aggregates. Although that amount will vary from individual to individual and from indication to indication, it is easily determined by one skilled in the art without undue experimentation. Compounds lIly may be administered by known conventional modes of therapeutic administration such as intraveneous, rectal and oral administration. Dose forms for administration of compounds Illy can be prepared by recognized methods in the pharmaceutical science.
The compound, 7 - {3R - hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 - (2 methylspiro[3.3]hept - 2 - yl) - lE - propenyl]cyclopent - lR - yllheptan - I - ol (TR-4852), which is represented by the formula
is particularly useful in a therapeutic method for inducing uterine contractions in an individual for whom such therapy is indicated by administering to that individual an amount of Compound TR-4852 above that is effective in inducing uterine contractions. Indications for use of Compound TR-4852 are any condition in which inducement of uterine contraction is desirable, such as inducement of labor. The term "effective uterine contracting amount" or any equivalent of the term means a dose or a series of doses that will induce uterine contraction. Although that amount will vary from individual to individual and from indication to indication, it is easily determined by one skilled in the art without undue experimentation. Compound
TR-4852 may be administered by known conventional modes of therapeutic administration such as intravenous, rectal or oral administration. Dose forms for administration of Compound TR-4852 can be prepared by recognized methods in the pharmaceutical science.
The following Table A illustrates preferred embodiments of the present invention compiled by Compound No., Example No. and identified by the
I.U.P.A.C. system of nomenclature.
Compound Example
No. No I.U.P.A.C. Nomenclature Chemical Abstracts Nomenclature
TR-4126 2A Methyl 7-{5-oxo-2R-[3S-hydroxy-3- Methyl 15S-hydroxy-16,18-methano-18,20 (spiro[3.3]hept-2-yl)-1E-propenyl]- methano-9-oxoprosta-10,13E-dien-1-oate cyclopent-3-en-1R-yl}heptanoate.
TR-4127 2B Methyl 7-{5-oxo-2R-[3R-hydroxy-3- Methyl 15R-hydroxy-16,18-methano-18,20 (spiro[3.3]hept-2-yl)-1E-propenyl]- methano-9-oxoprosta-10,13E-diencyclopent-3-en-1R-yl}heptanoate. 1-oate
TR-4120 1A Methyl 7-{3R-hydroxy-5-oxo-2R-[3R- Methyl 11α,15R-Dihydroxy-16,18-methanohydroxy-3-(spiro[3.3]hept-2-yl)-1E- 18,20-methano-9-oxoprost-13E-en-1-oate propenyl]cyclopent-1R-yl}heptanoate.
TR-4121 1B Methyl 7-{3R-hydroxy-5-oxo-2R-[3S- Methyl 11α,15R-dihydroxy-16,18-methanohydroxy-3-(spiro[3.3]hept-2-yl)-1E- 18,20-methano-9-oxoprost-13E-en-1-oate propenyl]cyclopent-1R-yl}heptanoate.
TR-4713 7A 7-{3R-hydroxy-5-oxo-2R-[3R-hydroxy- 16,18-Methano-18,20-methano-1,11α,15R3-(spiro[3.3]hept-2-yl)-1E-propenyl]- trihydroxyprost-13E-en-9-one cyclopent-1R-yl}heptan-1-ol.
TR-4714 7B 7-{3R-hydroxy-5-oxo-2R-[3S-hydroxy- 16,18-Methano-18,20-methano-1,11α,15S3-(spiro[3.3]hept-2-yl)-1E-propenyl]- trihydroxyprost-13E-en-9-one cyclopent-1R-yl}heptan-1-ol.
TR-4020 5A dl 7-{5-oxo-2R-[3R-hydroxy-3- (#) 15R-Hydroxy-16,19-ethano-19,20 (spiro[5.5]undec-3-yl)-1E- butano-9-oxoprost-13E-en-1-oic acid propenyl]cyclopent-1R-yl}heptanoic acid.
TR-4021 5B dl 7-{5-oxo-2R-[3S-hydroxy-3- (#) 15S-Hydroxy-16,19-ethano-19,20 (spiro[5.5]undec-3-yl)-1E- butano-9-oxoprost-13E-en-1-oic acid propenyl]cyclopent-1R-yl}heptanoic acid.
TR-4136 4A dl 7-{5-oxo-2R-[3S-hydroxy-3- (#) 15S-Hydroxy-16,18-methano-18,20 (spiro[3.3]hept-2-yl)-1E-propenyl]- methano-9-oxoprost-13E-en-1-oic acid cyclopent-1R-yl}heptanoic acid.
TR-4137 4B dl 7-{5-oxo-2R-[3R-hydroxy-3- (#) 15R-Hydroxy-16,18-methano-18,20 (spiro[3.3]hept-2-yl)-1E-propenyl]- methano-9-oxoprost-13E-en-1-oic acid cyclopent-1R-yl}heptanoic acid.
TR-4146 6A dl 7-{5-oxo-2R-[3S-hydroxy-3- (#) 15S-Hydroxy-16,18-methano-18,20 (spiro[3.3]hept-2-yl)-1E-propenyl]- methano-9-oxoprosta-5Z,13E-dien-1-oic cyclopent-1R-yl}hept-5Z-enoic acid.
TR-4147 6B dl 7-{5-oxo-2R-[3R-hydroxy-3- (#) 15R-Hydroxy-16,18-methano-18,20 (spiro[3.3]hept-2-yl)-1E-propenyl]- methano-9-oxoprosta-5Z,13E-dien-1-oic cyclopent-1R-yl}hept-5Z-enoic acid.
Compound Example
No. No. I.U.P.A.C. Nomenclature Chemical Abstracts Nomenclature
TR-4139 3A Methyl 7-{3R,5S-dihydroxy-2R-[3S- Methyl 16,18-methano-18,20hydroxy-3-(spiro[3.3]hept-2-yl)-1E- methano-9α,11α15S-trihydroxyprostpropenyl]cyclopent-1R-yl}heptanoate. 13E-en-1-oate
TR-4138 3B Methyl 7-{3R,5R-dihydroxy-2R-[3S- Methyl 16,18-methano-18,20-methanohydroxy-3-(spiro[3.3]hept-2-yl)-1E- 9 ,11α15S-trihydroxyprost-13E-en-1-oate propenyl]-cyclopent-1R-yl}heptanoate.
TR-4726 8A Ethyl 7-{3R-hydroxy-5-oxo-2R-[3R- Ethyl 11α,15R-dihydroxy-16,18-methanohydroxy-3-(spiro[3.3]hept-2-yl)-1E- 18,20-methano-9-oxoprosta-5Z,13E-dienpropenyl]cyclopent-1R-yl}hept-5Z-enoate. 1-oate
TR-4727 8B Ethyl 7-{3R-hydroxy-5-oxo-2R-[3S- Ethyl 11α,15S-dihydroxy-16,18-methanohydroxy-3-(spiro[3.3]hept-2-yl)-1E- 18,20-methano-9-oxoprosta-5Z-13E-dienpropenyl]cyclopent-1R-yl}hept-5Z-enoate. 1-oate
TR-4841 12A 7-{3R-hydroxy-5-oxo-2R-[3S-hydroxy- 16,18-Methyl-16,18-methano-18,20-methano3-(2-methylspiro[3.3]hept-2-yl)-1E- 1,11α,15S-trihydroxyprost-13E-en-9-one propenyl]-cyclopent-1R-yl}heptan-1-ol.
TR-4852 12B 7-{3R-hydroxy-5-oxo-2R-[3R-hydroxy- 16-Methyl-16,18-methano-18,20-methano3-(2-methylspiro[3.3]hept-2-yl)-1E- 1,11α,15R-trihydroxyprost-13E-en-9-one propenyl]-cyclopent-1R-yl}heptan-1-ol
TR-4842 13A Methyl 7-{3R-hydroxy-5-oxo-2R-[3S- Methyl 11α,15S-dihydroxy-16,-methyl-16,18hydroxy-3-(2-methylspiro[3.3]hept-2- methano-18,20-methano-9-oxoprost-13E -yl)-1E-propenyl]cyclopent-1R-yl}- en-1-oate
TR-4845 13B Methyl 7-{3R-hydroxy-5-oxo-2R-[3R- Methyl 11α,15R-dihydroxy-16-methyl-16,18hydroxy-3-(2-methylspiro[3.3]hept- methano-18,20-methano-9-oxoprost-13E2-yl)-1E-propenyl]cyclopent-1R-yl}- en-1-oate heptanoate
TR-4758 11B dl Methyl 7-{6-oxo-2R-[3S-hydroxy-3- dl Methyl 15S-hydroxy-9-oxo-9a-homo (spiro[3.3]hept-2-yl)-1E-propenyl]- 16,18-methano-18,20-methanoprost-5Z,13Ecyclohex-1R-yl}hept-5Z-enoate dien-1-oate
TR-4759 11A dl Methyl 7-{6-oxo-2R-[3R-hydroxy-3- dl Methyl 15R-hydroxy-9-oxo-9a-homo (spiro[3.3]hept-2-yl)-1E-propenyl]- 16,18-methano-18,20-methanoprost-5Z,13Ecyclohex-1R-yl}hept-5Z-enoate dien-1-oate In order to further illustrate the novel aspects of the present invention, the following Examples 1 to 8, 11 to 13 and 15 are presented. Compounds indentified by compound number in the following examples refer to the compounds compiled in Table A. The optical rotations were obtained at a temperature of about 22 C.
EXAMPLE 1
This Example illustrates a typical preparation of Prostaglandin E, Analogues.
Compounds TR 4120 and TR 4121 were prepared according to the procedure which follows. A mixture containing 2.62 grams (0.0059 moles) of 1 - iodo - 3RS (1 - ethoxyethoxy) - 3 - (spiro[3.3]hept-2-yl) - 1E - propene) see Example 9 for preparation) and 24 ml. of dry diethyl ether (distilled from benzophenone ketyl) was prepared and cooled to -78 C. with stirring under an argon atmosphere. Then 6.95 ml of 1.7 M t-butyllithium (0.0118 mole) in n-pentane was added and the mixture was stirred at a temperature of -78 C for 2 hours. A solution of 0.766 grams of Copper(l)pentyne (0.0059 moles) and 1.66 ml of hexamethylphosphorous triamide in 8 ml of dry diethyl ether was added to the reaction flask with stirring at -78 C. The resulting mixture was stirred 30 minutes at -78 C and 1.74 grams (0.0536 mole) of methyl 7[3R(tetrahydropyran-2-yloxy)-5-oxocyclopent-1-ethyl]heptanoate in 4.0 ml of dry diethyl ether was added thereto. The mixture was stirred for 30 minutes at -780C and subsequently brought to -200C and stirred for 1.5 hours. The mixture was quenched by the addition of 115 ml of 20% (v/v) aqueous ammonium sulfate and extracted with 50 ml of diethyl ether. Unless otherwise stated, the term "ether" is used in these Examples to denote diethyl ether. The aqueous material was extracted with 100 ml (2x50 ml) of ether. The ethereal extracts were combined and washed with 50 ml of 20/, (v/v) sulfuric acid. The aqueous material was back-extracted with 100 ml (2x50 ml) of ether. The combined ether extracts were filtered through diatomaceous earth ("Celite" Registered Trade Mark), washed with 50 ml of saturated sodium bicarbonate solution and subsequently washed with 50 ml of saturated sodium chloride solution. The washed ethereal extract was then dried over anhydrous magnesium sulfate, filtered through diatomaceous earth (Celite) and the solvent removed in vacuo. The residue was stirred with 12 ml of acetic acid-watertetrahydrofuran (65:35:10 v/v) at 220C for 15 hours. The solvents were removed in vacuo and the residue was taken up in 50 ml of water. The water mixture was extracted with 150 ml (3x50 ml) of ether-ethyl acetate (1:1 v/v). The organic mixture was washed with 50 ml of saturated sodium bicarbonate solution and then washed with 50 ml of saturated sodium chloride solution. The washed organic mixture was then dried over anhydrous magnesium sulfate, filtered through diatomaceous earth (Celite) and the solvents was removed in vacuo. The residue was chromatographed by column chromatography using an 85:15 (w/w) silicic acid: diatomaceous earth (Celite) support and using a benzene-ethyl acetate gradient elution to yield 168.4 mg of Compound TR 4120 and 162.8 mg of Compound TR 4121.
A. Compound TR 4120 had the following spectral properties:
Analysis-IR: #maxCHCl3 3600-3300-1, 2950 cm-1,
1740 cm-1 and 1710 cm-1 NMR(CDCl3): # 1.1-2.9, multiplet, 27H # 3.65, singlet, 3H # 3.6-4.2, multiplet, 3H # 4.6, multiplet, 1H # 5.6 ppm, multiplet, 2H [a]D (CHCI2, c. 0.87): -61.10 B. Compound TR 4121 had the following spectral properties:
Analysis-IR: smaXCHC'3 36003300 cm-', 2950 cm-1, 1740 cm-1 and 1710 cm-1
NMR(CDCl3): # 1.0-2.9, multiplet, 27H # 3.6, singlet, 3H # 3.6-4.1, multiplet, 3H # 4.6, multiplet, 1H # 4.5 ppm, multiplet, 2H [α]D (CHCl3, c. 1.0): -56.5
EXAMPLE 2
This Example illustrates the preparation of Prostaglandin A analogues.
A mixture, containing 0.1234 grams (0.315 m mole) of Compounds TR 4120 and Tr 4121, prepared as described in Example 1, and 3.5 ml of glacial acetic acid and 0.7 ml of water was heated at 60 C for 24 hours. The solvents were removed in vacuo and the residue was taken up in 20 ml of water and 20 ml of ether-ethyl acetate (1:1 v/v). The ether-ethyl acetate extract was washed with 20 ml of saturated sodium bicarbonate solution and then washed with 20 ml saturated sodium chloride solution. The washed extract was dried over anhydrous magnesium sulfate and filtered. The solvents were removed from the extract in vacuo. The residue was chromatographed by column chromatography using a silicic aciddiatomaceous earth -5:15 w/w) support and using a benzene-ethyl acetate gradient to yield 15.9 mg of compound TR 4126 and 27.6 mg of Compound TR 4127.
A. Compound TR 4126 had the following spectral properties:
Analysis-IR: #maxCHCl3 2940 cm-1, 1730 cm-1, and 1705 cm-1
NMR(CDCl3): # 0.9-2.5, multiplet, 25H
63.3, multiplet, 1H 6 3.7, singlet, 3H # 3.8-4.0, multiplet, 2H # 5.5, multiplet, 2H # 6.1, multiplet, 1H # 7.25 ppm, multiplet, 1H [α]D(CHCl3, c. 0.96): +83.5 .
B. Compound TR 4127 had the following spectral properties:
Analysis-IR: #maxCHCl3 2930 cm-1, 1730 cm-1, and 1710 cm-1
NMR(CDCl3): # 1.1-2.4,multiplet, 25H 6 3.2, multiplet, 1H # 3.63, singlet, 3H # 3.7-4.1, multiplet, 2H # 5.5, multiplet, 2H # 6.1, multiplet, 1H # 7.4 ppm, multiplet, 1H [α]D(CHCl3, c. 0.92); +77 .
EXAMPLE 3
This Example illustrates the preparation of Prostaglandin F1α and F1 analogues.
About 10 ml of anhydrous methanol was mixed with 0.11 grams (0.28 mmol) of
Compound TR 4120 prepared in the manner described in Example 1. The mixture was cooled in an ice-methanol bath and a mixture of 0.0635 grams (0.168 mmol) of sodium borohydride partially dissolved in 15 ml of anhydrous methanol was added.
The mixture was stirred for 30 minutes at -200C then brought to room temperature and stirred for an additional 2.5 hours. The solvents were removed in vacuo. The residue was taken up in 30 ml of water and extracted with 120 ml (4x30 ml) of ether-ethyl acetate (1:1 v/v). The ether-ethyl acetate extract were combined and washed with 30 ml of saturated sodium chloride solution. The washed extract was dried over anhydrous magnesium sulfate and filtered and the solvents were then removed in vacuo. The residue was chromatographed by column chromatography using silicic acid: diatomaceous earth (Celite) 85:15 (w/w) support and using a benzene-ethyl acetate gradient elution to yield 32.2 mg of TR 4139 and 28.2 mg of
TR 4138.
A. Compound TR 4139 had the following spectral properties
Analysis-IR: #maxCHCl3 3600-3100 cm-1, 2950 cm-1, and
1700 cm-1 NMR(CDCl3): 6 1.1-2.6, multiplet, 27H # 3.6-4.2, multiplet, 5H # 5.5, multiplet, 1H # 5.45 ppm, multiplet, 2H [α]D(CHCl3 c. 1.26): +32.2
B. Compound TR 4138 had the following spectral properties:
Analysis-IR: #maxCHCl3 3600-3100 cm-1, 2950 cm-1, and
1730 cm-1
NMR(CDCl3): # 1.1-2.6, multiplet, 27H 3.7, singlet, 3H # 3.7-4.1,multiplet, 5H # 5.5 ppm, multiplet, 2H [a]0(CHCl3,c. 1.41): +6.80.
EXAMPLE 4
Preparation of Compounds TR 4136 and TR 4137
A mixture containing 1.31 grams (0.00295 mole) of 1 - iodo - 3RS - (1 ethoxyethoxy) - 3 - (spiro[3.3]hept - 2 - yl) - 1E - propene (see Example 9 for preparation of this compound) and 12 ml of dry ether (distilled from benzophenone ketyl, b.p. 34"C) was prepared and cooled to -780C with stirring under an argon atmosphere. Then 3.475 ml (0.0059 mole) of a solution (1.7 M) oft - butyllithium in pentane was added. The resultant mixture was stirred for 2 hr at -780C.
Copper(l)pentyne (0.383 g, 0.00295 mole) and 0.83 ml of dry hexamethylphosphorous triamide in 4 ml of dry ether was added to the reaction flask. The resulting reaction mixture was stirred for 30 minutes at -780C and 0.6 grams (0.00268 mole) of methyl 7 - (S - oxocyclopent - 1 - enyl)heptanoate in 2 ml of dry ether was added thereto. The mixture was stirred for 30 minutes at -780C and subsequently brought to -200C and stirred for 90 minutes. The mixture was quenched with 80 ml of 20% (w/v) aqueous ammonium sulfate solution. The mixture was shaken for 10 minutes with 30 ml of ether. The aqueous material was extracted with 150 ml (2x75 ml) of ether. The ethereal extracts were combined and washed with 30 ml of cold 2% (v/v) aqueous sulfuric acid. The aqueous material was back-extracted with 100 ml (2x50 ml) of ether. The combined ether extracts were filtered through diatomaceous earth (Celite), washed with 75 ml of saturated sodium bicarbonate solution and subsequently with 75 ml of saturated sodium chloride solution. The washed extract was then dried over anhydrous magnesium sulfate, and filtered through diatomaceous earth (Celite) the solvents were removed from the extract in vacuo. The residue was stirred wit 25 ml of acetic acid-water-tetrahydrofuran (65:30:10 v/v) at about 22 C for 1 hour. The solvents were removed in vacuo and the residue was taken up in 30 ml of water and 30 ml of ether-ethyl acetate (1:1 v/v). The aqueous material was extracted with 70 ml (2x35 ml) of ether-ethyl acetate (1:1 v/v). The ether-ethyl acetate extracts were combined and washed with 50 ml of saturated sodium bicarbonate solution and then washed with 50 ml of saturated sodium chloride solution. The washed ether-ethyl acetate extracts were dried over anhydrous magnesium sulfate and filtered through diatomaceous earth (Celite). The solvents were removed from the extract in vacuo.
The residue was stirred with 25 ml of 5% (w/v) potassium hydroxide-methanolwater (1:1 v/v) for 2.5 hours. The methanol was removed in vacuo. The residual material was taken up in 50 ml of water and extracted with 90 ml (3x30 ml) o
B. Compound TR 4137 had the following spectral properties:
Analysis-IR: #maxCHCl3 3600 cm-1, 2940 cm-1, 1730 cm-1,
and 1710 cm-1
NMR(CDCl3): # 1.1-2.7, multiplet, 29H
3.9,multiplet, 1H
5.5, multiplet, 2H
6.95 ppm, broad singlet, 211 EXAMPLE S
Preparation of Compounds TR 4020 and TR 4021
Repeating in a similar manner the procedure of Example 4, but replacing
1 - iodo - 3 - RS - (1 - ethoxyethoxy) - 3 - (spiro[3.3]hept - 2 - yl) - 1E propene with 1 - iodo - 3RS - (1 - ethoxyethoxy - 3 - (spiro[5.5]undec - 3 - yl) 1E - propene (see Example 10 for preparation) yields the following 11 - deoxy
Prostaglandin E, analogues:
A. Compound TR 4020 had the following spectral properties:
Analysis-IR: #maxCHCl3 3600-2400 cm-1, 1950 cm-1, 1740 cm-1,
and 1720 cm-1
NMR(CDCl3): # 0.7-2.6, multiplet, 37H 6 3.9, multiplet, 1H 6 5.6, multiplet, 2H # 6.1 ppm, multiplet, 2H
B. Compound TR 4021 had the following spectral properties:
Analysis-IR: #maxCHCl3 3500-2400 cm-1, 1730 cm-1, and
1710 cm-1
NMR(CDCl3): # 0.7-2.6, multiplet, 37H
6 3.95, multiplet, 1H 6 5.7, multiplet, 2H # 6.01 ppm, multiplet, 2H
EXAMPLE 6
Preparation of Compounds TR 4146 and TR 4147
Repeating in a similar manner the procedure of Example 4, but replacing
methyl 7- (5- oxocyclopent - 1 - enyl)heptanoate with methyl 7- (5- oxocyclopent - 1 - enyl)hept- 5Z- enoate yields the following 11
deoxyprostaglandin E2 analogues.
A. Compound TR 4146 had the following spectral properties:
Analysis-IR: #maxCHCl3 2950 cm-1, 1730 cm-1, and
1710 cm-'
NMR(CDCl3): # 1.8-3.0, multiplet, 25H # 4.0, multiplet, 1H 6 5.45, multiplet, 4H â 7.2 ppm, broad singlet, 2H
B. Compound TR 4147 had the following spectral properties:
Analysis-IR: #maxCHCl3 2950 cm-1, 1740 cm-1 and
1715 cm-1 NMR(CDC13): # 0.8-3.0, multiplet, 25H
6 3.9 multiplet, 1H 6 5.45, multiplet, 4H a 6.9 ppm, broad singlet, 2H
EXAMPLE 7
Preparation of compounds TR 4713 and TR 4714
A solution of 606 mg (2.0 mmol) of 1 - iodo - 3RS - (I - ethoxyethoxy) - 3 (spiro[3.3]hept - 2 - yl) - 1E - propene in 11.0 ml of dry ether was stirred under argon at -78 , and 3.6 ml of 1.18 M t - butyllithium in pentane was injected. The reaction mixture was stirred for 2.5 hr at -78 , then was transferred into a stirred, -78 solution of 250 mg of copper(I)pentyne in 6.2 ml of dry ether (solubilized at 25 with 0.74 ml of hexamethylphosphorous triamide). The resultant complex was stirred for 0.5 hr at -78 , then a solution of 685 mg of 1 - tetrahydropyran - 2 yloxy - 7 - {3R - (tetrahydropyran - 2 - yloxy) - 5 - oxocyclopent - 1 enyl}heptane in 3.7 ml of ether was injected dropwise over 10 min. The reaction mixture was stirred for 0.5 hr at -78 , and 1.5 hr at -10 . The reaction was quenced by the addition of 20% aqueous ammonium sulfate and the mixture extracted with ether. The ethereal extracts were combined and washed with 2% aqueous sulfuric acid, saturated aqueous sodium bicarbonate and brine, then dried (MgSO4), filtered and solved removed in vacuo to yield an orange oil. The oil was stirred with 54 ml of 65:35:10 (v/v/v) acetic acid-water-THF for 18 hr at 25 . The solvents were removed by evaporation in vacuo and water added to the residue. The mixture was extracted with ether. The ethereal extracts were washed with saturated aqueous sodium bicarbonate and brine, then dried (MgSO4), filtered and ether evaporated in vacuo to afford 629 mg of crude products as a yellow oil. The products were purified by column chromatography to afford 82.8 mg of Compound TR 4714; and 103 mg of Compound TR 4713.
A. Compound TR 4713 had the following spectral properties: Analysis-IR:#maxCHCl3 2.78, 2.95 (broad), 5.75, 10.40
NMR(CDCl3): 5.66, multiplet, 2, CH=CH
3.2-4.3, multiplet, 7H, CHOH [α]D (CHCl3, c. 0.94): -57.9
Ms (70 eV) 346 (p-H2O)
328 (p-2H2O) B. Compound TR 4714 had the following spectral properties: Analysis-IR:#maxCHCl3 2.78, 5.75, 10.40
NMR(CDCl3): # 5.74, multiplet, 2H, trans-CH=CH)
3.2-4.7, multiplet, 7H, CHOH [α]D (CHCl3, c. 1.0): -53.5
Ms(70 eV) 346 (p-H2O)
328 (p-2H2O) EXAMPLE 8
Preparation of Compounds TR 4726 and TR 4727.
Repeating in a similar manner the procedure of Example 1, but replacing methyl 7 - [3R - (tetrahydropyran - 2 - yloxy) - 5 - oxocyclopent - 1 enyl]heptanoate with ethyl 7 - [3R - tetrahydropyran - 2 - yloxy) - 5
oxocyclopent - 1 - enyl]hept - 5Z - enoate yields the prostaglandin E2 analogues
TR 4726 and TR 4727.
A. Compound TR 4726 had the following spectral properties:
Analysis-IR: #maxCHCl3 910, 970, 1075, 1160, 1740, 2840,
2950, 3400, (broad), and 3600 cm-1.
NMR(CDCl3): #1.24, t, 3H, J=7HZ 1.4 to 3.0, m, 23H
3.3 to 4.3, m, 6H
5.2 to 5.7, m, 4H
Ms (70 eV): m/e 386 (p-H2O)
368 (p-2H2O)
341 (p-H2O-OC2H5
309 (p-C7H11)
291 (p-C7H11-H2O) [α]D (CHCl3, c 0.95): -53.1 .
B. Compound TR 4727 had the following spectral properties:
Analysis-NMR, IR, Ms are essentially the same as for the compound 4726 above.
[a]o (C11Cl3, c0.95): -60.00.
EXAMPLE 9
This Example illustrates the preparation of the intermediate compound 1 iodo - 3RS - (I - ethoxyethoxy) - 3 - (spiro[3.3]hept - 2 - yl) - lE - propene using the following procedure.
A. Preparation of l,l-di(hydroxymethyl)cyclobutane Lithium aluminium hydride (63.4 g, 1.67 mole) was slurried in 600 ml of dry ether (distilled from benzophenone ketyl, bp 340 C). The slurry was cooled in an ice-water bath and a mixture of 100 g (0.69 mole) of 1,1 - cyclobutanedicarboxylic acid (commercially available from Aldrich Chemical Co., Inc.) and 250 ml of dry ether was slowly added. The mixture was stirred at reflux for 1 hr, cooled and the excess hydride was destroyed by ethyl acetate addition, The mixture was treated with 1 liter of 6N hydrochloric acid and the products were extracted with 2 liters (4x500 ml) of ether. The organic material was washed with 250 ml of saturated sodium bicarbonate solution and 250 ml of saturated sodium chloride solution. It was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to yield 49 g of pure 1,1 - di(hydroxymethyl!cyclobutane.
Analysis-NMR(CDCl3): a 1.85, multiplet, 6H
a 3.3-3.8 ppm, multiplet, 4H
B. Preparation of 1,1 -di(Toluenesulfonyloxymethyl)cyclobutane 1,1 - di(Hydroxymethyl)cyclobutane (1.16 g, 0.01 mole) was mixed with 10 ml of dry pyridine (distilled from calcium hydride). The mixture was cooled to approximately OOC and 5.0 g (0.0263 mole) of p - toluenesulfonyl chloride was added portion wise. The mixture was stirred for 3 hrs at OOC then poured into 70 ml of cold 6N hydrochloric acid. Crude ditosylate was isolated by filtration. The crude material was recrystallized from methanol to yield 2.76 g (64.7%) of 1,1 di(toluenesulfonyloxymethyl)cyclobutane.
Analysis: NMR(CDCl3): a 1.8, broad singlet, 6H ô 2.45, singlet, 6H
a 3.95, singlet, 4H
a 7.5, AB pattern, J=8HZ, 8H
C. Preparation of Diethyl Spiro [3.3] heptane-2,2-dicarboxylate ester
Sodium metal (0.5 g, 0.022 mole) was dispersed in 10 ml of dry xylene (distilled from sodium hydride) by rapid stirring at 1100C. Diethyl malonate (6 g, 0.0375 mole, 5.67 ml) was added and the mixture was heated at 1000C until the sodium was consumed. 1,1 - di(toluene sulfonyloxymethyl)cyclobutane (4 g, 0.009425 mole) was added and the mixture was heated at 1570C for 18 hr with stirring. The mixture was cooled and 20 ml of water was added. The phases were separated and the aqueous material was extracted with 150 ml (2x75 ml) of xylene. The organic material was washed with 50 ml of 6N hydrochloric acid and 50 ml of saturated sodium sulfate solution. It was dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo. The residue was distilled at reduced pressure to yield 0.99 g (44 /n) of diethyl spiro[3.3]heptane - 2,2 - dicarboxylate.
Analysis-bp 98--98.5"C/0.35 mm NMR(CDCl3): a 1.25, triplet, 6H, J=7HZ a 1.5-2.2, multiplet, 6H
a 2.48, multiplet, 4H
4.2 ppm, quartet, 4H, J=7HZ
D. Preparation of Spiro [3.3]heptane-2,2-dicarboxylic acid
Spiro[3.3]heptane - 2,2 - dicarboethoxy ester (14.4 g, 0.6 mole) was mixed with 13.45 g (0.24 mole) of potassium hydroxide and 114 ml of ethanol. The mixture was refluxed for I hr, cooled and then filtered. The cake was washed with 80 ml of absolute ethanol. The residue was dissolved in 50 ml of water and acidified with 60 ml of 50% aqueous sulfuric acid. The mixture was cooled and filtered to yield 10.4 g of spiro[3.3]heptane - 2,2 - dicarboxylic acid.
Analysis--NM R(CDCI,): a 1.3-2.2, multiplet, 6H
2.5, multiplet, 4H 8.9.0 ppm, broad singlet, 2H
E. Preparation of Spiro[3.3]heptane-2-carboxylic acid
Crude spiro[3.3]heptane - 3,3 - dicarboxylic acid (8.3 g, 0.046 mole) was thermally decarboxylated by heating the material at 2200 C for 30 min. Heating was discontinued when the evolution of carbon dioxide ceased. The mixture was cooled to yield 5.38 g of spiro[3.3]heptane - 2 - carboxylic acid.
Analysis-NMR(CDCl3): ô 1.5-2.3, multiplet, IIH 11.0 ppm, broad singlet, 1H
F. Preparation of Spiro[3.3]heptane-2-carboxylic acid chloride
Spiro[3.3]heptane - 3 - carboxylic acid (8.5 g, 0.06 mole) was mixed with 14.5 g (0.124 mole, 9.2 ml) of thionyl chloride. The mixture was allowed to stir overnight at room temperature. The excess thionyl chloride was removed by distillation at atmospheric pressure. Spiro[3.3]heptane - 2 - carboxylic acid chloride (8.3 g, 86.4%) was isolated by distillation at reduced pressure.
Analysis-NMR(CDCl3): a 1.8-2.6, multiplet, 10H
3.45 ppm, multiplet, 1H
G. Preparation of l-Chloro-3-(spiro[3.3]hept-2-y1)- lE-propen-3-one A 100 ml of 3-neck round bottom flask was fitted with a mechanical stirrer, gas
inlet tube extending below the solvent surface and a water condenser with a gas
outlet. The system was flushed with acetylene gas (bubbled through an activated
aluminum oxide trap, two concentrated sulfuric acid traps and an empty trap for 3
min. Carbon tetrachloride (70 ml) was added to the flask and the system flushed with acetylene for 3 min. The flask was cooled in an ice-water bath and 8.3 g (0.053
mole) of anhydrous aluminum chloride was added. The system was flushed with
acetylene for 3 min. The gas inlet was replaced with an addition funnel and 8.3 g (0.053 mole) of spiro[3.3]heptane - 2 - carboxylic acid chloride was added slowly over a 10 min. period. The addition funnel was replaced with the gas inlet tube and acetylene was bubbled through the mixture for 4 hr. The mixture was poured into
100 ml of crushed ice and 150 ml of saturated sodium chloride solution. The phases were separated and the aqueous material was extracted with 195 ml (3x65 ml) of ether. The combined organic extracts were washed with 150 m1(3x50 ml) of 10% (v/v) aqueous hydrochloric acid solution, 150 ml (3x50 ml) of saturated sodium bicarbonate solution and 100 ml of saturated sodium chloride solution. The material was dried over anhydrous magnesium sulfate, filtered and the solvents were removed in vacuo. The material was distilled at reduced pressure to yield 7.3 g (75.7%) of 1 - chloro - 3 - (spiro[3.3]hept - 2 - yl) - tE - propen - 3 - one.
Analysis-b.p. 650--680C/0.2 mm NMR(CDCl3): a 1.5-2.5, multiplet, 10H owt 3.3, multiplet, 1H o 6.4, doublet, 1H J=14HZ a 6.4, doublet, 1H J=14HZ a 7.2 ppm, doublet, 1H J=14Hz
H. Preparation of l-Iodo-3-(spiro[3.3]hept-2-yl)lE-propen-3-one 1 - Chloro - 3 - (spiro[3.3]hept - 2 - yl) - 1E - propen - 3 - one (7.3 g, 0.042 mole) was mixed with 25.2 g (0.168 mole) of sodium iodide and 45 ml of dry acetone (distilled from anhydrous potassium carbonate, b.p. 56"C). The mixture was refluxed with rapid stirring overnight. The mixture was cooled and the solvent was removed in vacuo. The solid residue was taken up in 75 ml of water and the products were extracted with 150 ml (3x50 ml) of ether. The organic material was washed with 50 ml of saturated sodium bicarbonate solution, 50 ml of aqueous sodium thiosulfate solution and 50 ml of saturated sodium chloride solution. The material was dried over anhydrous magnesium sulfate, filtered and the solvent was removed in vacuo to yield 6.9 g (62.2%) of crude 1 - iodo - 3 - (spiro[3.3]hept - 2 yl) - 1E - propen - 3 - one.
Analysis-NMR(CDCl3): a 1.5-2.4, multiplet, 10H or 3.3, multiplet, 1H owt 6.9, doublet, 1H, J=lSHZ a 7.5 ppm, doublet, 1H, J=lSHZ
I. Preparation of 1-Iodo-3-(spiro[3.3]hept-2-yl)1E-propen-3RS-ol
1 - Iodo - 3 - (spiro[3.3]hept - 2 yl) - 1E - propen - 3 - one (8.62 g, 0.0311 mole) was dissolved in 100 ml of absolute ethanol and the mixture cooled to-20 C.
Sodium borohydride (4.71 g, 0.124 mole) was dissolved in 100 ml of absolute ethanol and added to the cooled mixture. The mixture was allowed to stir for 1 hr at 0 C. The solvent was removed in vacuo and the residue was taken up in 250 ml of water. The products were extracted with 300 ml (3x 100 ml) of ether. The extracts were washed with 75 ml of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and the solvent removed in vacuo to yield 7.5 g of I - iodo - 3 - (spyro[3.3]hept - 2 - vI) - lE - propen - 3RS - ol.
Analysis-NMR(CDCl3): S 1.5-2.5, multiplet, 11H a 3.8, multiplet, 1H ô 6.06.5 ppm, multiplet, 2H
J. Preparation of 1 - Iodo - 3RS - (I - ethoxyethoxy) - 3 - (spiro[3.3]hept - 2
yl) - 1E - propene.
1 - Iodo - 3 - (spiro[3.3]hept - 2 - yl) - 1E - propen - 3RS - ol (7.5 g, 0.027 mole) was mixed with 38.2 g (50 ml, 0.512 mole) of ethyl vinyl ether. Phosphorus oxychloride (2 drops) was added and the mixture was allowed to stir overnight at room temperature. The mixture was poured into 75 ml of saturated sodium bicarbonate solution and the products were extracted with 100 ml (2x50 ml) of ether. The organic material was washed with 50 ml of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and the solvent was removed in vacuo. Chromography was performed on silica gel 60 (0.063-0.2 mm.
7230 mesh, ASTM) using benzene eluant to yield 5.3 g (56.4%) of 1 - iodo 3RS - (1 - ethoxyethoxy) - 3 - (spiro[3.3]hept - 2 - yl) - 1E - propene.
Analysis-NMR(CDCl3): #0.8-25, multiplet, 17H a 3.5, multiplet, 3H a 4.6, quartet, 1H, J=SHZ
a 6.3 ppm multiplet, 2H
EXAMPLE 10
This Example illustrates the preparation of the intermediate compound I iodo - 3RS - (1 - ethoxyethoxy) - 3 - (spiro[5.5]undec - 3 yl) - 1E - propene using the following procedure.
A. Preparation of Spiro[5.5]undecane - 3 - carboxylic acid chloride
In a procedure as described in Example 9F, spiro[5.5]undecane - 3carboxylic acid chloride was prepared from thionyl chloride and spiro[5.5]undecane - 3 - carboxylic acid (preparation described in U.S. Patent No.
3,350,442).
Analysis-NMR(CDCl3): a 0.62.4, multiplet, 1 8H
B. Preparation of 1 - Chloro - 3 -(spiro[5.5]undec - 3 - yl) - 1E - propen - 3
one.
In a procedure as described in Example 9G, 1 - chloro - 3 (spiro[5.5]undec - 3 - yl) - 1E - propen - 3 - one was prepared from anhydrous aluminum chloride, spiro[5.5]undecane- 3- carboxylic acid chloride and acetylene. The compound was purified by column chromatography on silica gel 60 (0.063 4.2 mm, 70-230 mesh, ASTM) using chloroform as the solvent.
Analysis-NMR(CDCl3): a 0.62.6, multiplet, 19H 6.5, doublet, 1H, J=1SHZ
7.3 ppm, doublet, 1H,J=15Hz
C. Preparation of 1 - Iodo - 3 -soiro[5.5]undec - 3 - yl) - 1E - propen - 3 - one.
In a procedure as described in Example 9H, 1 - chloro - 3 (spiro[5.5]undec - 3 - yl) - 1E - propen - 3 - one was reacted with sodium iodide in acetone to yield 1 - iodo - 3 - (spiro[5.5]undec - 3 - yl) - 1E - propen - 3 - one (70.9%).
Analysis-NMR(CDCl3): #0.8-2.5, multiplet, 19H a 7.22, doublet, 1H, J=16HZ a 7.85 ppm, doublet, 1H, J=16HZ
D. Preparation of 1 - Iodo - 3 - (spiro[5.5]undec - 3 - yl) - 1E - propen - 3RS
ol.
In a procedure as described in Example 91, 1 - iodo - 3 - (spiro[5.5]undec - 3
yl) - 1E - propen - 3 - one was reduced with sodium borohydride in ethanol to yield
1 - - iodo - 3 - (spiro[5.5]undec - 3 - yl) - lE - propen - 3RS - ol (98.5%).
Analysis-NMR(CDCl3): # 0.5-2.2, multiplet, 19H # 3.95, multiplet, 1H # 6.1-6.8 ppm, multiplet, 2H
E. Preparation of 1 - Iodo - 3RS - (I - ethoxyethoxy) - 3 -(spiro[5.5]undec - 3
yl) - 1E - propene.
In a procedure as described in Example 9J, 1 - iodo - 3RS - (1 - ethoxyethoxy) - 3 - (spiro[5.5]undec - 3 - yl) - 1E - propene was prepared from 1 - iodo - 3 -(spiro[5.5]undec - 3 - yl) - 1E - propen - 3RS - ol and ethylvinyl ether using phosphorous oxychloride as a catalyst. The compound was obtained in 76.9% yield.
Analysis-NMR(CDCl3): a 0.7-2.1, multiplet, 25H a 3.6, multiplet, 3H a 4.7, quartet, 1H, J=6Hz a 6.1-6.6 ppm, multiplet, 2H
EXAMPLE 11
Preparation of Compounds TR-4758 and TR-4759.
Repeating in a similar manner the procedure of Example 7, but replacing 1
tetrahydropyran - 2 - yloxy - 7 - {3R - (tetrahydrofuran - 2 - yloxy) - 5
oxocyclopent - 1 - enyl}heptane with methyl 7 -(6 - oxocyclohex - 1 - enyl)hept 5Z - enoate yields the 9a - homo prostaglandin E2 analogues TR-4758 and TR
4759.
A. Compound TR-4759 had the following spectral properties: Analysis-IR#maxCHCl3 2.78, 2.85 (broad), 3.4, 5.80,
5.85, 10.40
NMR(CDCl3): # 3.66, singlet, 3H
3.92, multiplet, 1H
5.40, multiplet, 4H
Ms(70eV): m/e 388 (p)
370 (p-H2O)
357 (p-OCH3) 352 (p-2H2O) B. Compound TR-4758 had the following spectral properties:
Analysis-IR, NMR and Ms are essentially the same as compound TR-4759 above.
EXAMPLE 12
Preparation of compounds TR-4841 and TR-4852.
Repeating in a similar manner the procedure of Example 7, but replacing 1 iodo - 3RS - (1 - ethoxyethoxy) - 3 - (spiro[3.3]hept - 2 - yl) - 1E - propene with 1 iodo - 3RS - (tetrahydropyran - 2 - yloxy) - 3 - (2 - methylspiro[3.3]hept - 2 yl) - 1E - propene yields the prostaglandin analogues TR-4841 and TR-4852.
A. Compound TR-4841 had the following spectral properties: Analysis-IR#max CHCl3 2.78, 2.88(broad), 5.75, 10.4
NMR(CDCl3); # 1.00, singlet, 3H
3.60, triplet, J=5.0 Hz, 2H
4.0, multiplet, 2H
5.67, multiplet, 2H [α]D(CHCl3, c 0.89) -53.8
Ms(70eV)m/e: 360(@-H2O) 342 (p-2H2O) 269 (p-C8H13)
B. Compound TR-4852 had the following spectral properties: Analysis-IR#max CHCl3 2.78, 2.94(broad), 10.4
NMR(CDCl3); # 1.08, singlet, 3H
3.10, broad singlet, 3H
3.65, broad triplet, 2H
3.90, multiplet, 2H
5.60, multiplet, 2H [α]D(CHCl3, c 0.89) -43.8
Ms(70eV) m/e: 360(p-H2O) 342 (p-2H2O) 269 (P-C8H13) 251 (p-C8H13-H2O) EXAMPLE 13
Preparation of compounds TR-4842 and TR-4845.
Repeating in a similar manner the procedure of Example 1, but replacing 1
iodo - 3RS - (1 - ethoxyethoxy) - 3 - (spiro[3.3]hept - 2 - yl) - 1E - propene with
1 - iodo - 3RS - (tetrahydropyran - 2 - yloxy) - 3 - (2 - methylspiro[3.3]hept - 2
yl) -1E - propene yields prostaglandin analogues TR-4842 and TR-4845.
A. Compound TR-4842 had the following spectral properties: Analysis-IR:#maxCHCl3 2.78, 2.90, 5.75, 10.4
NMR(CDCl3); # 1.02, singlet, 3H
3.66, singlet, 3H
4.02, multiplet, 2H
5.65, multiplet, 2H [α]D(c 0.87, CHCl3) -64.1
Ms(70eV) m/e: 388(p-H2O)
339(p-2H2O-OCH3)
317 (p-OC113-C9H9) 297 (p-C8H13) B. Compound TR-4845 had the following spectral properties:
Analysis-IR, Ms spectra essentially the same as for compound TR-4842 above.
NMR(CDCl3): #1.08, singlet, 3H
3.66, singlet, 3H
3.96, multiplet, 2H
5.60, multiplet, 2H [α]D(c 0.86, CHCl3) -44.8
EXAMPLE 14
This Example illustrates the preparation of the intermediate compound 1iodo - 3RS - (tetrahydropyran - 2 - yloxy) - 3 - (2 - methyspiro[3.3]hept - 2 yl) - 1E - propene using the following procedure.
A. Preparation of 2-Methylspiro[3.3]heptane-2-carboxylic acid.
A slurry of 2.15 g (44.2 mmol) of sodium hydride (50% in oil) in 45.0 ml of dry
THF was stirred under argon at -200C. A solution of 5.52 g (40.0 mmol) of sprio[3.3]heptane-2-carboxylic acid in 5.0 ml of dry THF was added dropwise. The reaction mixture was stirred for 0.5 hr at -20 C. A solution of 4.5 mmol of freshylprepared, -20 C lithium diisopropylamide in 31.0 ml of THF was added to the reaction mixture. The reaction mixture was stirred for 0.3 hr at 0 C. Methyl iodide (2.80 ml, 44.5 mmol) was added, and the reaction mixture stirred an additional 2.0 hr at 25 C. The reaction mixture was cooled to -20 C and the reaction quenched by careful addition of cold 10% aqueous HCl. The mixture was extracted with 1:1 ethyl acetate-ether. The extracts were washed with brine, then dried (MgSO4), filtered, and solvents evaporated in vacuo. The residue was dissolved in 1 N NaOH and extracted three times with ether. The aqueous layer was acidified with 6 N HCI and extracted with 1:1 (v/v) ethyl acetate-ether. These extracts were washed with brine, dried (MgSO4), filtered and evaporated in vacuo to yield 5.1 g of 2 methylspiro[3.3]heptane - 2 - carboxylic acid as a light yellow oil (82.5%).
Analysis-NMR(CHCl3): # 1.35, singlet, 3H
11.4, broad singlet, 1H.
B. Preparation of 2-Methyl-2-acetylspiro[3.3]heptane.
A solution of 5.0 g (33.0 mmol) 2 - methylspiro[3.3]heptane - 2 - carboxylic acid in 33.0 ml of dry ether was stirred under argon at 0 C and 47.6 ml (74.3 mmol) of 1.56 M methyl lithium in ether added dropwise. The reaction mixture was allowed to warm to 25 C and was stirred for 3.0 hr. The reaction mixture was cooled to -20 C and quenched by addition of 10% aqueous HCl. The layers were separated and the aqueous layer extracted with ether. The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, then dried (MgSO4), filtered, and evaporated in vacuo to afford 2- methyl - 2acetylspiro[3.3]heptane as a light yellow oil (4.91 g 98%).
Analysis-NMR(CDCl3): # 1.35, singlet, 3H
2.0, singlet, 3H IR: #maxCHCl3 3.85, 7.40, 8.80 .
C. Preparation of (2 - Methylspiro[3.3]hept - 2 - yl) - (2 - hydroxyvinyl)ketone.
A solution of 7.8 g (130.0 mmol) methyl formate and 4.91 g (32.4 mmol) of 2 methyl - 2 - acetylspiro[3.3]heptane in 8.0 ml of dry ether was dropped into a slurry of 1.2 g of sodium hydride in 180 ml of ether. A few drops of MeOH were added and the reaction mixture stirred for 1.5 hr at 25 C. The reaction mixture was cooled to -10 C and the reaction quenched by slow addition of water. The layers were separated and the aqueous layer extracted twice with ether. The combined organic extracts were washed with water and 1 N NaOH. The combined aqueous layers were acidified with 6 N HCl and extracted with ether. The ether extracts were washed with brine, then dried (MgSO4), filtered and evaporated in vacuo to yield 4.0 g of (2 - methylspiro[3.3]hept - 2 - yl) (2 - hydroxyvinyl)ketone as a yellow oil (69.5%).
Analysis-IR: #maxCHCl3 3.85, 7.40, 8.80
NMR(CDCl3) # 1.32, singlet, 3H
5.5, doublet, J=4.0 Hz, 1H
7.90, doublet, J=4.0 Hz, 1H
8:05, singlet, 1H
D. Preparation of 1 - Chloro - 3 - (2 - methylspiro[3.3]hept - 2 - yl) - 1E
propen - 3 - one.
A solution of 4.0 g of (2 - methylspiro[3.3]hept - 2 - yl) (2 - hydroxyvinyl-ketone in 25.0 ml of benzene was added dropwise with stirring to 3.95 g of thionyl chloride.
The reaction mixture was allowed to stand for 18 hr at 250 C. The product was isolated by distillation (high vacuum) to afford 2.66 g 1 - chloro - 3 - (2 methylspiro[3.3]hept - 2 - yl) - 1E - propen - 3 - one - as a yellow oil (40%).
Analysis-bp 65-750C Rf(CHCl3) 0.21
E. Preparation of 1 - Iodo - '3- - (2 - methylspiro[3.3]hept - 2 - yl) - 1E
propen - 3 - one.
In a procedure as described in Example 9H, 1 - chloro - 3 (2 methylspiro[3.3]hept - 2 yl) - 1E - propen - 3 - one was reacted with sodium iodide in acetone to yield 1 - iodo - 3 - (2 - methylspiro[3.3]hept - 2 - yl) - 1E propen - 3 - one (87%).
Analysis-NMR(CDCl3) 81.32, singlet, 3H 7.22, doublet, J=14 Hz, 1H
7.85, doublet, J=14 Hz, 1H
F. Preparation of 1 - Iodo - 3RS - hydroxy - 3 - (2 - methylspiro[3.3]hept - 2
yl) - 1E - propene.
In a procedure as described in Example 9I, 1 - iodo - 3 (2 methylspiro[3.3]hept - 2 - yl) - 1E - propene - 3 - one was reduced with sodium borohydride in ethanol to yield 1 - iodo - 3RS - hydroxy - 3 - (2 methylspiro[3.3]hept - 2 yl) - 1E - propene (100%).
Analysis-NMR(CDCl3): S 1.35, singlet, 3H 3.34.0, multiplet, 2H
6.35, multiplet, 2H
IR: AmaXCHCI3 2.78, 2.95 (broad), 6.20, 7.25,
7.25, 10.3, 10.5,u G. Preparaton of I - Iodo - 3RS - (tetrahydropyran - 2- yloxy)- 3 - (2
methylspiro[3.3]hept - 2 - yl) - lE - propene.
Crude 1 - iodo - 3RS - hydroxy - 3 - (2 - methylspiro[3.3]hept - 2 - yl - lE - propene (3.31 g) was dissolved in 12.0 ml dry ether and stirred under argon at 250C.
Distilled dihydropyran (1.25 ml) was added, followed by a small spatula of p toluenesulfonic acid. The reaction mixture was allowed to stand for 2 hr at 25"C. then partitioned between ether and saturated aqueous NaHCO3. The organic layer was dried (MgSO4), filtered, and evaporated in vacuo to afford 4.43 g crude 1 iodo - 3RS - (tetrahydropyran - 2 - yloxy) - 3 - (2 - methylspiro[3.3]hept - 2 yl) - 1E - propene as a crude orange oil. Purification by column chromatography on Silica Gel afforded 2.90 g of the compound as a clear oil.
AnalysisNMR(CDCla): S 1.32, singlet, 3H
3.50, multiplet, 1H
3.75, multiplet, 2H
4.60, broad singlet, 1H EXAMPLE 15
A. Evaluation of Inhibition of Human Platelet Aggregation by Analogues of
Prostaglandins Structure III.
The ability of test compounds to inhibit platelet aggregation was determined
by a modification of the turbidometric technique of Born (Nature, 194:927 [1962]).
Blood was collected from human volunteers who had not ingested aspirin or
aspirin-containing products within the preceding two weeks in heparinized
containers and was allowed to settle for one (1) hour). The platelet rich plasma
(prp) supernates were collected and cooled. Siliconized glassware was used
throughout.
In a representative assay 1.9 ml of PRP and 0.2 ml of test compound at the
appropriate concentrations (0.001 to 100 mcgm), or 0.2 ml of distilled water
(control procedure) were placed in sample cuvettes. The cuvettes were placed in a 37"C incubation block for 15 minutes, and then in a spectrophotometer linked to a
strip chart recorder. After 30-60 seconds, 0.2 ml of a solution, prepared by
diluting a calf-skin collagen solution 1:9 with Tyrodes' Solution, was added to each
cuvette. Platelet aggregation was evidenced by a decrease in optical density.
Calculation of the degree of inhibition of platelet aggregation exhibited by
each concentration of test compound was accomplished according to the method
of Caprino et al., (Arzneim-Forsch, 23:1277 [1973]). An EDso value was then
determined graphically. Activity of the compounds was scored as follows: ED, (mcg/kg) Activity Value
No activity 0
> 1.0 1 > 0.111.0 2 > 0.01s0.1 3 > 0.001 < 0.01 4 10.001 5
B. Evaluation of the Effects of Prostaglandin Analogues III on Gastric Secretion in
the Rat.
A procedure based on that described by Lipmann (J. Pharm. Pharmacol., 21:335 [1968]) was used to assess the influence of test compounds on gastric secretion. Rats of one sex weighing 150 to 200 g were randomly divided into groups of six animals each and fasted for 48 hours previously to the experiments, water being available adlibitum. The animals were anesthetized with ether, the abdomen was opened through a midline incision and the pylorus was ligated. Test compounds were diluted from stock solution so as to administer a dose of 1.5 mg/kg in a volume equivalent to 1 ml/kg. Subcutaneous injections were applied immediately after surgery and again 2 hours later, so that a total dose of 3.0 mg/kg was administered. Dilutions were made with phosphate buffer (pH 7.38) as recommended by Lee et al. (Prostaglandins 3:29 [1973]), in order to insure adequate stability of drugs at the subcutaneous depot. Each compound was tested in one group of rats; an additional control group received only the vehicle.
Four hours after pyloric ligation the animals were killed with ether, the cardias ligated and the stomachs removed. The volume of gastric secretion was measured and the contents centrifuged at 500 rpm for 10 minutes. Total acid in the supernatant was titrated against a 0.1 N sodium hydroxide solution and the amount expressed in mEq.
Volume and total acid values of the treated group were compared with those of the controls by the "T" test. Anti-secretory activity was scored according to the following scale:
% decrease in acidity Activity Value
< 26 0 26-50, not significant 1 26-50, significant 2 51-75 3 76-100 4
C. Evaluation of the Effects of Prostaglandin Analogues III on Femoral Blood
Flow in the Dog.
The peripheral vasodilator or constrictor effects of these compounds were determined in mongrel dogs of either sex, weighing between 10 and 20 kg anesthetized intravenously with 35 mg/kg of sodium pentobarbital. An external iliac artery was dissected immediately above the femoral arch for a length of approximately 5 cm and a previously calibrated, non-connulating electromagnetic flowmeter sensor with a lumen between 2.5 and 3.5 mm was placed snugly around the vessel. Cannulas were placed in a branch of the artery arising distally to the location of the flowmeter sensor for intraaterial drug administrations, in the contralateral femoral artery for systemic blood pressure recordings and in the trachea for artificial respiration with room air. Femoral blood flow and systemic blood pressure were continuously recorded with an electromagnetic flowmeter and pressure transducer, respectively.
After an adequate control period, test compounds were injected intraarterially at one log-spaced doses ranging from 0.001 to 10 mcg., in a volume of 0.5 ml and at 5 to 10 minute intervals. Maximum changes in bloodflow, as well as any variations in blood pressure, were tabulated for each dose in absolute values (ml/min. and mmHg). the calculations were made taking as control values those existing immediately before administration of each dose. The direction of the observed change (plus for increase and minus for decrease) was also noted. The dose changing bloodflow by 100 mVmin (ED,OOmUmin) was calculated graphically and was used for scoring activity as follows: ED,,mVmin, mcg Activity Value
> 10.0 0 1.01-10.0 1
0.111.0 2 0.010.1 3
D. Evaluation of the Effects of Prostaglandin Analogues III on Blood Pressure and
Heart Rate in the Anesthetized Cat.
The acute effects of test compounds on blood pressure and heart rate were
determined in cats of either sex anesthetized with a mixture of pentobarbital sodium (35 mg/kg, i.v.) and barbital sodium (100 mg/kg, i.v.). Cannulas were placed
in the trachea to allow adequate spontaneous ventilation, in a femoral artery for
blood pressure recording with a strain gage transducer, and in a saphenous vein for drug administration. Heart rate was recorded by means of a cardiotachometer driven by the R wave of the electrocardiogram. After a period of 10 minutes of stable recordings of blood pressure and heart rate, the test compound was
administered intravenously at doses increasing from 0.01 to 10.0 mcg/kg, spaced one log and injected at 10 minutes intervals. All doses were injected in a volume of 0.1 mVkg. Modifications of blood pressure and heart rate induced by the test compound were expressed both in absolute units (mmHg and beats/minutes) and as percent of values recorded immediately before administration of each dose.
Biphasic responses were tabulated in the order in which they occur. The direction of the observed changes was also noted (+ for increases and - for decreases).
Activity of compounds in this test was judged only on the basis of the degree of hypotension observed. Thus, the ED90 mmHg (dose decreasing blood pressure by 50 mmHg) was calculated graphically and the compound scored according to the following scale:
ED50 mm11g, mcg/kg Activity Value
> 10.0 0 1.01-10.0 1
0.111.0 2 0.01 ".1 3
Table D summarizes the results of the preceding assays A to D utilizing the preferred examples.
* TABLE B
Summary of Activity of Prostaglandin Analogues III in; Test A: inhibition of
Human Platelet Aggregation; Test B: Inhibition of Rodent Gastric Secretion; Test C:
Increase in Canidae Femoral Blood Flow; and Test D: Decrease in Normal Feline
Blood Pressure and Heart Rate.
TABLE B
Example Activity Value
TRNo. No. Test A Test B Test C Test D
4126 2A 1 NT NT O
4127 2B 1 NT NT O
4120 1A 3 2 0 0
4121 1B 1 1 2 0
4020 SA 1 0 0 0
4021 SB 1 0 0 0
4136 4A 1 1 0 0
4137 4B 1 3 3 2
4146 6A 1 0 0 0
4147 6B 1 0 0 2
4139 3A 1 0 0 0
4138 3B 1 NT NT O
4713 7A 1 4 NT NT
4714 7B 1 0 NT NT
4841 12A 1 0 NT NT
4852 12B I 2 NT NT
4842 13A 1 0 NT NT
4845 13B 3 3 NT NT
4726 8A 1 0 NT NT
4727 8B 1 0 NT NT
4758 11B 1 0 NT NT
4759 11A 1 0 NT NT
NT: Not tested
E. Evaluation of Cascade Assay Effects by Analogues of Prostaglandin Structure
III
The smooth muscle stimulant effects of test compounds were determined simultaneously in four different tissues that are known to be reactive to naturally occurring prostaglandins. Segments of rat stomach fundus, rat colon, chick rectum and rabbit aortic strip were obtained as described by: Vane, J. R. Brit. J.
Pharmacol, 12:344 (1957); Regoli, D. and Vane, J. R., Brit. J. Pharmacol., 23:351 (1964); Mann, M. and West, G.B., Brit. J. Pharmacol., 5: 173 (1950); and
Furchgott, R. F. and Bhadrakom, R., J. Pharmacol. Exper. Ther., 108:129 (1953).
One end of each preparation was tied to the bottom of a 10 ml tissue chamber and the other to a force displacement transducer (Grass FT-03) for continuous tension recording. The stomach, colon, and rectum segments were stretched to an initial tension of 1 g, while the aortic strip was subjected to 4 g. All preparations were left undisturbed for 1 hour prior to testing. The chambers were equipped with an external jacket through which water, maintained at 400 C, was circulated.
Preparations were arranged one beneath the other in descending order (aorta, stomach, colon and rectum). Provision was made for bathing the four tissues successively so that they were superfused with the same fluid (Gaddum, H. J., Brit.
J. Pharmacol., 6:321 [1953]). The bathing fluid consisted of: Krebs bicarbonate solution aerated with a mixture of 95% O2 and 5% CO2 and warmed at 370C; atropine sulphate (0.1 mcg/ml), phenoxybenzamine hvdrochloride (0.1 mcit(ml), propaneol hydrochloride (3.0 mcg/ml), methysergide maleate (0.2 mcgSml) and brompheniramine maleate (0.1 mcg/ml) were added to eliminate the possibility of smooth muscle responses being due to stimulation of cholinerglc, adrenergic, serotonin or histamine receptors. The fluid was circulated by means of a roller pump and was allowed to drip over the preparations at a rate of 10 minute.
Test compounds were diluted from stock solutions so as to administer quantities ranging from 0.001 to 100,000 ng in a volume of 0.5 ml. The compounds were applied by dripping on the uppermost tissue, at intervals of 10 to 20 minutes.
Maximal increases in tension after each dose were measured and the results were used to plot dose-response curves. ED, data (doses necessary to produce a response 50% of maximum) were then calculated graphically for each tissue.
Maximum responses utilized were those elicted by PGE, in gastric and rectal tissue, by PGF2 in colonic tissue, and by PGA2 in aortic tissue.
Activity in each tissue was scored according to the following scale: ED90, ng Activity Value
> 10000 0 1001-10000 1 101-1000 2
10-100 3
< 10 4
F. Evaluation of the Effects of the Rat Uterus in Vitro by Analogues of
Prostaglandin Structure III
The uterine stimulant effect of test compounds was determined in segments of uterus obtained from rats (140--160 g) pretreated subcutaneously with 1 mg/kg of diethyl-stilbesterol 18 hours before the experiment. The tissues were placed in 10 ml chambers filled with de-Jalon solution at 290 C, were aerated and bubbled with 95% O2 and 5% CO2, and were prepared for isometric recording with force displacement transducers. Preparations were stretched to an initial tension of 1 g and were left undisturbed for 30 minutes. Carbachol (1 mcg/ml) was then added to the bath and a response was recorded. After a ten minute interval the carbachol procedure was repeated. Responses to increasing concentrations of a test compound (0.001 to 10 mcg/ml with one log intervals) were then recorded every 10 minutes. Preparations were washed four times after each response. All doses of compounds were administered in a 0.1 ml volume. Because it has been observed that the magnitude of the second response to carbachol (approximately 10% greater than the first) is close to the maximal response of the tissue, such value was taken as a measure of the sensitivity of a particular segment. Responses to each concentration of the test compound were expressed in terms of percentage of the second response to carbachol and the EDso (dose producing a response 50% that of carbachol) was calculated graphically. Activity was scored according to the following scale: ED, (mcg/ml) Activity Value
> 10 0 1.001-10 1 0.101-1.0 2 0.01 ".1 3
< 0.01 4
G. Evaluation of the Effects on the Guinea Pig Trachea in Vitro by Analogues of
Prostaglandin Structure III
A male guinea pig weighing 200500 g was killed by a blow on the head. A 20 mm length of the trachea was dissected from the animal, transferred to a petri dish containing Kreb's solution (aerated with 95% O2 and 5% CO2 at 370 C), and cut longitudinally opposite the tracheal muscle. The tissue was then cut transversely three quarters of the distance across, a second cut in the opposite direction (again three quarters of the distance across the tissue) was made and the procedure was continued for the whole tissue. The ends of the trachea were pulled to form a zigzag shaped strip. The tracheal strip used in the experiment was approximately 30 mm when extended under 0.25--0.5 g load in the tissue bath. Cotton thread was tied to one end of the tissue, and linen thread to the other. It was attached via the linen thread to a glass hook in a 5 ml isolated tissue bath containing Krebs' solution (37"C, aerated with a mixture of 95% O2 and 5% CO2). The opposite end was attached via cotton to an isotonic Harvard transducer (Model 386 Heart/Smooth
Muscle Transducer, Harvard Apparatus). The load on the transducer lever was small, usually 0.3 g, with a range of 0.25--0.5, g, and the magnification high, 80 fold using an appropriate twin-channel pen recorder. A minimum of thirty minutes was allowed before applying a test compound to the tissue. Test compounds were then applied (in volumes of 0.5 ml) at thirty minute intervals, being in contact with the tissue for five minutes followed by an overflow washout time of twenty seconds.
Prostaglandin E, at a bath concentration of 0.1 mcg/ml, was then tested repeatedly on two such strips, obtained from two different animals, until two responses (the values of which are recorded) differing by no more than 25% occur.
A test compound was then added to the same two strips at bath concentrations of 0.01, 0.1, 1.0, and 10.0 mcg/ml and the effects of the compound were recorded.
After the test compound had been evaluated at the highest concentration, PGE, was retested at 0.1 mcg/ml (and the value of the response recorded) to insure that the viability of the strips was retained during the experiment. The mean of the effects of the test compound on the two strips was then calculated for each concentration, and, based on the resulting values, an activity value was assigned as follows:
Activity
Response Value
More relaxation at 0.01 mcg/ml than that elicited by PGEt R4
More relaxation at 0.1 mcg/ml than that elicited by PGE1 R3
More relaxation at 1.0 mcg/ml than that elicited by PGE1 R2
More relaxation at 10.0 mcg/ml than that elicited by PGE1 Rl No effect at any concentration greater than that elicited by PGE1 More contraction at 10.0 mcg/ml than the degree of
relaxation elicited by PGE1 Cl More contraction at 1.0 mcg/ml than the degree of
relaxation elicited by PGE1 C2
More contraction at 0.1 mcg/ml than the degree of relaxation
elicited by PGE1 C3
More contraction at 0.01 mcg/ml than the degree of
relaxation elicited by PGE1 C4
H. Evaluation of Antagonistic Effects on the Guinea Pig Ileum in Vitro by
Analogues of Prostaglandin Structure III
The degree and specificity of antagonism of test compounds to the smooth
muscle stimulant effects of prostaglandins were assessed in segments of terminal
guinea pig ileum. Preparations were placed in tissue chambers filled with Ringer
Tyrode solution at 370 C. bubbled with a mixture of 95% O2 and 5% CO2, and arranged for isometric recording with force displacement transducers. The segments were stretched to an initial tension of 1 g, and responses to a test concentration of acetylcholine (0.1 mcg/ml) were obtained every 5 minutes until two similar responses were observed (usually after four administrations).
Responses to acetylcholine (0.1 mcg/ml), PGE1 (0.1 mcg/ml), BaCl2 (100 mcg/ml) and PGF2 < (1 mcg/ml) were obtained (and recorded) in that order at S minute intervals before and after 100 seconds of incubation with 0.1 and 1.0 mcg/ml of the test compound. Any direct contractile effect of the test compound was recorded and evaluated in terms of mean values in grams of tension developed at each concentration. Responses to the different agonists observed after incubation with the test compound were expressed as percent of control responses. All drugs were administered in a volume of 0.1 ml.
Antagonism to prostaglandins was scored independently for PGE1 and PGF2, according to the following criteria:
Activity
Response Value 0
Lees than 50% blockade of PG responses 0
More than 50% blockade of PG responses and more than
10% antagonism of Ach and/or Bacl2, or production
of direct contraction 1
More than 50% blockade of PG responses at 1 mcg/ml with
less than 11% antagonism of Ach and BaCl2 without
production of direct contraction 2
Table C summarizes the results of the preceding assays E to H utilizing the preferred examples.
TABLE C
Summary of Activity of Prostaglandin Analogues III in:
Test E: Cascade Assay
Test F: Rat Uterus
Test G: Guinea Pig Trachea
Test H: Antagonistic Effects on Guinea Pig Ileum
TR Example Test E Test F Test G Test H
o 0 C 38=t Antagonism a No. No. > PGE1 PGF
Claims (56)
- 4126 2A 0 0 0 0 NT Cl 0 14127 2B 0 0 0 0 0 C1 0 14120 1A 0 0 1 0 0 C4 0 04121 1B 0 0 0 0 0 C1 0 04020 5A 2 0 0 0 0 R0 0 04021 SB 4 0 0 0 0 CO 0 04136 4A 2 0 1 0 0 C2 0 04137 4B 1 0 NT 0 0 C1 0 04146 6A 1 2 NT 0 0 C0 0 04147 6B 2 0 2 1 0 R0 0 14139 3A 0 0 0 0 0 C1 0 04138 3B 0 0 0 0 0 C1 0 04713 7A 0 0 1 0 0 C2 0 04714 7B 0 0 0 0 0 C1 0 04841 12A 0 0 0 0 0 C0 0 04852 12B 0 0 0 0 2 C0 0 04842 13A 0 0 0 0 0 R0 0 04845 13B 0 0 0 0 0 C4 1 04726 8A 0 0 0 0 0 C4 1 04277 8B 0 0 0 0 0 C2 0 04758 11B 0 0 0 0 0 C1 0 04759 11A 0 0 0 0 0 C4 0 0 NT: not tested WHAT WE CLAIM IS: 1. A compound having the formula:wherein: D is a R - hydroxymethylene or S - hydroxymethylene radical; J is a methylene, R - hydroxymethylene or S - hydroxymethylene; K is a methylene or ethylene provided that K is ethylene only when J is methylene, or J and K together form a vinylene radical; L is a carbonyl R - hydroxymethylene or S - hydroxymethylene radical; Q is an ethylene or Z - vinylene radical; T is an alkoxy carbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical, carboxyl, or hydroxymethyl radical; and B is a monospiroalkyl radical of the formula:where m isO, 1, or 2; n is an integer from 1 to 4 and p is an integer from 3 to 11 such that the sum of the integers m and n is less than or equal to 4, and wherein G is hydrogen or alkyl of 1 to 3 carbon atoms, or a pharmacologically acceptable nontoxic salt thereof when T is a carboxyl radical.
- 2. A compound according to claim 1 wherein m is 1 or 2, n is 1 or 2; and p is an integer from 3 to 5.
- 3. A compound according to claim 1 or 2 wherein L is carbonyl; K is methylene and J is R - hydroxymethylene, S - hydroxymethylene or methylene.
- 4. A compound according to claim 3 wherein J is R - hydroxymethylene or S hydroxymethylene, Q is ethylene; and T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 5. A compound according to claim 3, wherein J is R - hydroxymethylene or S - hydroxymethylene; Q is ethylene; and T is hydroxymethyl.
- 6. A compound according to claim 3, wherein J is R - hydroxymethylene or S - hydroxymethylene; Q is Z - vinylene; and T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxy radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 7. A compound according to claim 3, wherein J is R - hydroxymethylene or S - hydroxymethylene; Q is Z - vinylene; and T is hydroxymethyl.
- 8. A compound according to claim 3, wherein J is methylene; Q is ethylene; and T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 9. A compound according to claim 3, wherein J is methylene; Q is ethylene; and T is hydroxymethyl.
- 10. A compound according to claim 3, wherein J is methylene; Q is Z vinylene; and T is alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 11. A compound according to claim 3, wherein J is methylene; Q is Z vinylene; and T is hydroxymethyl.
- 12. A compound according to claim 1 or 2 wherein L is carbonyl and J and K together form a vinylene radical,
- 13. A compound according to claim 12, wherein Q is ethylene and T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 14. A compound according to claim 12, wherein Q is ethylene and T is hydroxymethyl.
- 15. A compound according to claim 12, wherein Q is Z-vinylene and T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 16. A compound according to claim 12, wherein Q is Z-vinylene and T is hydroxymethyl.
- 17. A compound according to claim 1 or 2, wherein L is R - hydroxymethylene or S - hydroxymethylene; K is methylene; and J is R - hydroxymethylene or S hydroxymethylene.
- 18. A compound according to claim 17, wherein Q is ethylene and T is an alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 19. A compound according to claim 17, wherein Q is ethylene and T is hydroxymethyl.
- 20. A compound according to claim 17, wherein Q is Z-vinylene and T is an alkoxycarbonyl having from 1 to 3 carbon atoms in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 21. A compound according to claim 17, wherein Q is Z - vinylene and T is hydroxymethyl.
- 22. A compound according to any one of claims 1 to 3, 12 and 17, in which G is hydrogen and n is an integer from 2 to 4.
- 23. A compound according to any one of the preceding claims having the formula:and D, J, K, L, Q, T and B arenas defined in claim 1.
- 24. A compound according to claim 1, wherein L is carbonyl; K is ethylene and J is methylene.
- 25. A compound according to claim 24, wherein Q is ethylene; and T is alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 26. A compound according to claim 24, wherein Q is ethylene and T is hydroxymethyl.
- 27. A compound according to claim 24, wherein Q is Z - vinylene and T is alkoxycarbonyl having from 1 to 3 carbon atoms inclusive in the alkyl radical or a carboxyl radical or a pharmacologically acceptable non-toxic carboxy salt thereof when T is a carboxyl radical.
- 28. A compound according to claim 24, wherein Q is Z - vinylene and T is a hydroxymethyl.
- 29. Methyl 7 - f3R - hydroxy - 5 - oxo - 2R - [3S - hydroxy - 3 (spiro[3.3]hept - 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}heptanoate.
- 30. Methyl 7 - {3R - hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 (spiro[3.3]hept - 2 - yl) - lE - propenyl]cyclopent - 1R - yl}heptanoate.
- 31. Methyl 7 {3R - hydroxy - 5 - oxo - 2R - [3S - hydroxy - 3 (2 merhylspiro[3.3]hept - 2 yl) - 1E - propenyl]cyclopent - 1R - yl}heptanoate.
- 32. Methyl 7 - {3R - hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 - (2methylspiro[3.3]hept - 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}heptanoate.
- 33. 7 - f3R - Hydroxy - 5 - oxo - 2R - [3S - hydroxy - 3 - (spiro[3.3]hept 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}heptan - 1 - o1.
- 34. 7 - f3R - Hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 - (spiro[3.3]hept 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}heptan - 1 - o1.
- 35. 7 - f3R - Hydroxy - S - oxo - 2R - [3S - hydroxy - 3 - (2 methylspiro[3.3]hept - 2 - yl) - lE - propenyl]cyclopent - 1R - yllheptan - 1 - ol.
- 36. 7 - {3R - Hydroxy - S-oxo- 2R - [3R - hydroxy - 3 - (2 - methylspiro[3.3]hept -2 -yl) - 1E - propenyl]cyclopent - lR - yliheptan - I - ol.
- 37. Ethyl 7 - f3R - hydroxy - 5 - oxo - 2R - [3S - hydroxy - 3 (spiro[3.3]hept - 2 - yl)lE - propenyl]cyclopent - 1R - yl}hept - SZ - enoate.
- 38. Ethyl 7 - {3R - hydroxy - 5 - oxo - 2R - [3R - hydroxy - 3 (spiro[3.3]hept - 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}hept - 5Z - enoate.
- 39. dl - 7 - [5 - Oxo - 2R - [3S - hydroxy - 3 - (spiro[5.5]- undec - 3 yl) 1E - propenyl]cyclopent - 1R - yl}heptanoic acid.
- 40. dl - 7 - {5 - Oxo - 2R - [3R - hydroxy - 3 - (spiro[5.5]undec - 3 yl) 1E - propenyl]cyclopent - 1R - yl}heptanoic acid.
- 41. dl - 7 - {5 - Oxo - 2R - [3S - hydroxy - 3 - (spiro[3.3]hept - 2 yl) - 1E propenyl]cyclopent - 1R -yl}heptanoic acid.
- 42. dl - 7 - {5 - Oxo - 2R - [3R - hydroxy - 3 (spiro[3.3.]hept - 2 - yl) - 1E propenyl]cyclopent - 1R - yl}heptanoic acid.
- 43. dl - 7 - {5 - Oxo - 2R - [3S - hydroxy - 3 - (spiro[3.3.]hept - 2 -yl) -1E propenyl]cyclopent - 1R - yl}hept - 5Z - enoic acid.
- 44. dl - 7 - {5 - Oxo - 2R - [3R - hydroxy - 3 - (spiro[3.3]hept -2 - yl) - 1E propenyl]cyclopent - 1R - yl}hept - 5Z - enoic acid.
- 45. dl - Methyl 7 - {6 - oxo - 2R - [3S - hydroxy - 3 - (spiro[3.3]hept - 2 yl) - 1E - propenyl]cyclohex - 1R - yl}hept - 5Z - enoate.
- 46. dl - Methyl 7 - {6 - oxo - 2R - [3R - hydroxy - 3 - (spiro[3.3.]hept - 2 yl) - 1E - propenyl]cyclohex - 1R - yl}hept - 5Z - enoate.
- 47. Methyl 7 - {5 - oxo - 2R - [3R - hydroxy - 3 - (spiro[3.3]hept - 2 - yl) 1E - propenyl]cyclopent - 3 - en - 1R - yl}heptanoate.
- 48. Methyl 7{5 - oxo - 2R - [3S - hydroxy - 3 - (spiro[3.3]hept - 2 - yl) 1E - propenyl]cyclopent - 3 - en - 1R - yl}heptanoate.
- 49. Methyl 7 - {3R,5S - dihydroxy - 2R - [3S - hydroxy - 3 - (spiro[3.3]hept 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}heptanoate.
- 50. Methyl 7 - {3R,5R - dihydroxy - 2R - [3S - hydroxy - 3- (spiro[3.3]hept - 2 - yl) - 1E - propenyl]cyclopent - 1R - yl}heptanoate.
- 51. A process for preparing a compound as defined in claim 1 which comprises contacting a compound of the formula:where X is an iodine or bromine atom; A is an acid-labile hydroxyl - protecting group selected from 1 - ethoxyethyl, trimethylsilyl, tert - butyl - dimethylsilyl, 1 ethoxy - 1 - methylethyl, tetrahydropyran - 2 - yl and triphenylmethyl radicals; and B is as defined in claim 1, with metallic lithium or lower alkyl lithium in an inert solvent under an inert atmosphere; contacting the reaction mixture with a [hexamethylphosphorous triamide], copper(I)pentyne, tri - n - butylphosphine copper(I)iodide, hexamethylphosphorous triamide - copper(I)iodide or copper(I)thiophenolate; and contacting the resultant reaction mixture with a compound of the formula:wherein J' is a methylene or =CHOA radical where A is a hydroxyl protecting group as defined above; K' is methylene or ethylene provided that K is ethylene only when J' is methylene; T' is an alkoxycarbonyl, having from 1 to 3 carbon atoms inclusive in the alkyl radical, or -CH2OA radical; and Q is as defined in claim 1; in an inert solvent for a period of time sufficient for a substantial degree of conjugate 1, 4 addition to take place to form an acid-labile hydroxyl protected intermediate compound, hydrolyzing the so-formed intermediate compound, to obtain a first compound having the formula:wherein B, D, Q and K' are as defined above, T" is (C,~3 akoxy)carbonyl or hydroxymethyl and J" is methylene, R-hydroxymethylene or Shydroxymethylene. a) if desired hydrolyzing the first compound, when T" is alkoxycarbonyl to obtain a second compound having the formula:wherein B, D, Q, K' and J" are as defined above; b) if desired reducing the first compound to obtain a third compound having the formula:wherein B, D, Q, K', J" and T" are as defined above and/or c) if desired dehydrating the first compound, when J" is R - hydroxymethylene or S - hydroxymethylene and K' is methylene, to obtain a fourth compound having the formula:wherein B, D, Q and T" are as defined above.
- 52. A process according to claim 51 substantially as hereinbefore described.
- 53. A compound as defined in claim 1 whenever prepared by a process as claimed in claim 51 or 52.
- 54. A compound as defined in claim 22 whenever prepared by a process as claimed in claim 51.
- 55. A pharmaceutical composition which comprises a compound as claimed in any one of claims 1 to 50, 53 or 54, together with a pharmaceutically acceptable diluent or carrier.
- 56. A composition according to claim 55 in which the compound is one claimed in claim 22 or 54.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65722276A | 1976-02-11 | 1976-02-11 | |
US05/758,124 US4098823A (en) | 1976-02-11 | 1977-01-10 | Monospiroalkyl derivatives of prostaglandins |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1568553A true GB1568553A (en) | 1980-05-29 |
Family
ID=27097362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB3182/77A Expired GB1568553A (en) | 1976-02-11 | 1977-01-26 | Monospiroalkyl derivatives of prostaglandins |
GB33373/78A Expired GB1569252A (en) | 1976-02-11 | 1977-01-26 | 3-monospiroalkyl-3-hydroxy-1-halo propene derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB33373/78A Expired GB1569252A (en) | 1976-02-11 | 1977-01-26 | 3-monospiroalkyl-3-hydroxy-1-halo propene derivatives |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPS52116444A (en) |
DE (1) | DE2705590C3 (en) |
FR (1) | FR2355820A1 (en) |
GB (2) | GB1568553A (en) |
NZ (1) | NZ183136A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725291A (en) * | 2015-02-12 | 2015-06-24 | 领思科技(大连)有限公司 | XPO1 inhibitor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5468734U (en) * | 1977-10-21 | 1979-05-16 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL43571A (en) * | 1972-11-08 | 1977-08-31 | Pfizer | Omega-pentanorprostaglandins and their preparation |
-
1977
- 1977-01-20 NZ NZ183136A patent/NZ183136A/en unknown
- 1977-01-26 GB GB3182/77A patent/GB1568553A/en not_active Expired
- 1977-01-26 GB GB33373/78A patent/GB1569252A/en not_active Expired
- 1977-02-09 JP JP1257577A patent/JPS52116444A/en active Pending
- 1977-02-10 DE DE2705590A patent/DE2705590C3/en not_active Expired
- 1977-02-10 FR FR7703808A patent/FR2355820A1/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725291A (en) * | 2015-02-12 | 2015-06-24 | 领思科技(大连)有限公司 | XPO1 inhibitor |
Also Published As
Publication number | Publication date |
---|---|
DE2705590A1 (en) | 1977-08-18 |
GB1569252A (en) | 1980-06-11 |
FR2355820A1 (en) | 1978-01-20 |
DE2705590B2 (en) | 1978-11-09 |
NZ183136A (en) | 1978-11-13 |
JPS52116444A (en) | 1977-09-29 |
DE2705590C3 (en) | 1979-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4132738A (en) | Preparation of 15-deoxy-16-hydroxyprostaglandins | |
US4171331A (en) | 1 And 2-substituted analogues of certain prostaglandins | |
PL121307B1 (en) | Processs for preparing novel derivatives of 15-desoxy-16-substituted-prostanic acidehhenno-prostanovojj kisloty | |
US4149017A (en) | Intermediates for the preparation of bicycloalkyl derivatives of prostaglandins | |
US4127612A (en) | 19-Hydroxy PGE1 carbinol analogues | |
US3984424A (en) | P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins | |
EP0073397A1 (en) | Enol acylate analogs of E1 and E2 prostaglandins | |
US4098823A (en) | Monospiroalkyl derivatives of prostaglandins | |
GB1568553A (en) | Monospiroalkyl derivatives of prostaglandins | |
US4220795A (en) | Cyclobutyl substituted derivatives of prostaglandin analogs | |
US4149007A (en) | C14 Phenyl-substituted derivatives of prostaglandin analogues | |
US4275224A (en) | 15-Deoxy-16-hydroxy prostaglandins | |
US4206127A (en) | 5,6-Dihydro analogues of prostaglandin I2 | |
DE2719901A1 (en) | PGE AND 11-DEOXY-PGE COMPOUNDS WITH A METHYLENE GROUP ON THE C-9 | |
US4833157A (en) | Methods of inhibitng gastric secretion with prostaglandin derivatives | |
US4100357A (en) | Depentyl analogues of PGA1 | |
IL45171A (en) | 11-substituted-11-desoxy-pge2 analogues | |
US4029698A (en) | Cycloalkylidenol analogues of prostaglandins E and F | |
DD140745A5 (en) | PROCESS FOR THE PRODUCTION OF NEW PROSTAGLANDINES | |
US4099017A (en) | Depentyl analogues of PGF1 | |
US4415592A (en) | 15-Deoxy-16-hydroxy prostaglandins for producing bronchodilation | |
US4331688A (en) | Therapeutic method for inhibiting gastric secretion by administration of 15-deoxy-16-hydroxy prostaglandins | |
CA1112240A (en) | Bicycloalkyl derivatives of prostaglandins | |
US4158018A (en) | 3-Oxa carbinol prostaglandin analogs | |
JPS6033429B2 (en) | Prostaglandin-like compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |